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Anna Victoria Justis 
Recruitment and function of ORP1L on the Coxiella burnetii parasitophorous vacuole 
 
Coxiella burnetii, the zoonotic agent of human Q fever and chronic endocarditis, 
is an obligate intracellular bacterial pathogen. The Coxiella intracellular niche, a large, 
lysosome-like parasitophorous vacuole (PV), is essential for bacterial survival and 
replication. There is growing evidence that host cell cholesterol trafficking plays a critical 
role in PV development and maintenance, prompting an examination of the role of 
cholesterol-binding host protein ORP1L (Oxysterol binding protein-Related Protein 1, 
Long) during infection. ORP1L is a multi-functional cholesterol-binding protein involved 
in late endosome/lysosome (LEL) trafficking, formation of membrane contact sites 
between LEL and the endoplasmic reticulum (ER), and cholesterol transfer from LEL to 
the ER. ORP1L localizes to the PV at novel membrane contact sites between the ER and 
the PV membrane. Ectopically expressed ORP1L in Coxiella-infected cells localizes to the 
PV membrane early during infection, before significant PV expansion and independent 
of other PV-localized proteins. Further, the N-terminal ORP1L Ankyrin repeats are both 
necessary and sufficient for PV localization, suggesting that protein-protein interactions, 
and not protein-lipid interactions, are primarily involved in PV association. Coxiella 
employs a Type IVB Secretion System (T4BSS) to translocate effector proteins into the 
host cytoplasm and manipulate various cellular functions. ORP1L is not found on the PV 
of a Coxiella mutant lacking a functional T4BSS, indicating a secreted bacterial protein is 
likely responsible for ORP1L recruitment. We identified a Coxiella mutant with a 
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transposon insertion in CBU_0352 that exhibits a 50% decrease in ORP1L recruitment, 
suggesting that Coxiella CBU_0352 interacts directly or indirectly with ORP1L. Finally, we 
found that ORP1L depletion using siRNA alters PV dynamics, resulting in smaller yet 
more fusogenic Coxiella PVs. Together, these data suggest that ORP1L is specifically 
recruited to the PV, where it plays a novel role in Coxiella PV development and 
interactions between the PV and the host cell. 
 
Stacey D. Gilk, Ph.D., Chair 
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Chapter I. Background and Rational 
 
Q fever and Coxiella burnetii 
Historic perspective 
 In 1935, an outbreak of unknown febrile disease was observed among 
slaughterhouse workers in Brisbane, Queensland, Australia.  Edward Derrick endeavored 
to identify the etiological source of the illness named “Q” fever for “query” fever of 
unknown cause.  When blood was transferred from the infected workers to guinea pigs 
in the laboratory, the guinea pigs also developed febrile disease [1].  At nearly the same 
time, an unidentified infectious agent was discovered during field studies in Montana, 
USA.  Ticks collected in Nine Mile valley caused febrile illness in the guinea pigs on which 
they fed.  Ultimately, a laboratory acquired infection with the Nine Mile agent resulted 
in researchers comparing the two isolates and immunological cross-protection studies 
confirmed that these illnesses were caused by the same organism [2].  The bacteria was 
named Coxiella burnetii after researchers Cox and Burnet who each contributed to its 
characterization. 
 Once the bacteria was identified, the world continued to see outbreaks of Q 
fever (reviewed in [3]).  For example, eight separate outbreaks occurred among Allied 
soldiers in southern Europe during World War II, and domestic outbreaks occurred in 
Amarillo, Texas and Chicago, Illinois during the mid-1940s [4-6].  These events were 
connected to livestock and revealed the aerosol route of transmission as well as the 
potential public health impact of C. burnetii infection [7].  Additional laboratory acquired 
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infections at the National Institutes of Health revealed that the bacteria has a low 
infectious dose [8, 9].  During the Cold War, the American military identified C. burnetii 
as a possible agent of biological warfare.  Experiments carried out at Dugway Proving 
Ground in Utah established the feasibility of such use and a small number of human 
experiments carried out in the 1950s clarified the dynamics of C. burnetii infection [10-
12].  Analysis of these early studies together with data from inhaled infection models in 
guinea pigs has determined the median inhaled infectious dose to be between 1 and 15 
organisms [13-15].  Due to these concerns, C. burnetii remains classified as a category B 
potentially aerosolized biological weapon under the Centers for Disease Control Select 
Agent program [16]. 
Animal infection 
 Q fever is a zoonotic disease that is endemic worldwide and affects humans as 
well as a broad range of animals.  C. burnetii  is likely enzootic in domestic ruminants as 
well as wild animals [17, 18] and has been isolated from mammals, birds [19], reptiles 
[20], and ticks [2].  While many studies have isolated C. burnetii from ticks and 
laboratory experiments have shown that several species of tick can serve as a C. burnetii 
vector, transmitting the bacteria by blood meal or transovarially, the actual risk of 
disease transmission in the field is not clear (reviewed in [21]).   
 Infected animals shed the small cell variant (SCV) form of C. burnetii into the 
environment via bodily secretions, including urine, feces, milk, and birth products.  C. 
burnetii is commonly found in raw milk, for example, and consumption of contaminated 
unpasturized milk can cause human infection [22].  One survey of milk samples from 134 
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commercial processing plants in 41 states found C. burnetii DNA in 95.5% of samples 
[23].  Another study of milk from 316 bulk storage tanks, each containing milk pooled 
from a herd of dairy cattle, found the 94.3% of samples tested positive for C. burnetii by 
PCR [24].  Furthermore, bacteria from infected animals can be disseminated into the 
environment, where it can remain viable on fomites for years [25].  Contaminated soils 
can become aerosolized and lead to human infection by inhalation.  There is a high 
prevalence of antibodies against C. burnetii among livestock in the USA: 41.6% of goats, 
16.5% of sheep, and 3.4% of cattle are seropositive for antibodies against C. burnetii 
[17], leading to a somewhat high risk of human exposure. 
 It follows that exposure to domestic ruminants results in the greatest number of 
C. burnetii human infections [26, 27].  This is supported by the finding from individual 
case studies and outbreak investigations, that occupational exposures in research 
facilities, farm environments, and slaughterhouses are commonly reported (reviewed in 
[17]).  One study tracked human Q fever cases in Germany and observed the seasonality 
of community outbreaks shift from primarily occurring in winter-spring to primarily 
occurring in spring-summer.  This shift followed changes in the temporal patterns of 
sheep husbandry in the region [28].  This exposure route is also supported by the 
sources of recent Q fever outbreaks in Europe.  29 human cases were identified in a 
small town in the French Alps during the spring seasons of 1995 and 1996.  The 
outbreak was traced to contaminated sheep waste from a nearby slaughterhouse [29].  
The largest human Q fever epidemic ever recorder occurred in the Netherlands from 
2007-2010, during which over 4000 human cases were identified.  This outbreak spread 
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from a dairy goat farm that experienced C. burnetii-related spontaneous abortion rates 
of up to 80% among its herd during the onset of the human outbreak [30, 31].   
Human infection 
 C. burnetii infection in humans is most often asymptomatic and self-limiting.  For 
example, during one Q fever outbreak in Switzerland during the early 1980s, 415 
infections were diagnosed by serology.  Of these cases 54% were asymptomatic and 
interestingly, only 12.5% of infected children showed symptoms [32].  In the 40% of 
patients who develop acute symptomatic disease, this manifests as fever and flu-like 
symptoms.  Rarely, Q fever may present as acute neurological disease or as a hyper-
inflammatory syndrome associated with hepatitis [33, 34].  Additionally, weakness and 
tiredness persisting for years and termed Q Fever Fatigue Syndrome has been observed 
in approximately 20% of acute Q fever patients [35, 36].  Regardless of whether the 
primary infection is symptomatic or asymptomatic, a small number of infections lead to 
chronic Q fever [32, 37].  Chronic Q fever can manifest months to years after initial 
infection and most often presents clinically as endocarditis [38].  Houpikian et al. 
determined that C. burnetii is responsible for approximately half of blood culture 
negative cases of infectious endocarditis [39].  Left untreated, Q fever endocarditis can 
be fatal [40].  Regardless of the specific manifestation, an 18-month course of treatment 
with doxycycline and chloroquine is the recommended treatment for human C .burnetii 
infection and can prevent relapse in greater than 95% of Q fever endocarditis patients 
[41, 42].   
5 
 Treating Q fever in pregnant women poses particular challenges [43].  Active C. 
burnetii infection during pregnancy can result in poor outcomes including fetal growth 
retardation, premature delivery, spontaneous abortion, or stillbirth [44].  One study of 
patients diagnosed with Q fever during pregnancy observed complications in 80 % of 
mothers who were not treated for the infection.  Furthermore, the worst outcomes 
were observed among mothers who were infected during the first trimester [45].  
Although no controlled human studies have been conducted, treatment of pregnant 
patients with chloroquine for long periods is contraindicated due to evidence of fetal 
harm seen in animal studies.  Since 1996, treatment with cotrimoxazole for at least 5 
weeks has been used to treat pregnant Q fever patients, reducing the risk of fetal and 
maternal complications [43].  Because cotrimoxazole is bacteriostatic, however, 
bactericidal treatment must be administered after delivery in order to clear the 
infection [46].  
 The clinical presentation of Q fever is variable and often non-specific, very likely 
resulting in underreporting and an underestimation of the incidence among humans.  
Between 1948 and 1986, a total of 1,396 human cases of Q fever were included in 
national disease surveillance reports for the USA [17].  In Germany, an annual incidence 
of 0.1-3.1 per million for human Q fever was observed between 1979-1999 [28].  Due to 
number of asymptomatic infections, actual disease incidence is likely much higher than 
that found in these studies. 
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Intracellular niche 
 C. burnetii is an obligate intracellular bacteria, only replicating within a niche 
intracellular compartment termed the Coxiella-containing vacuole (CCV) or the 
parasitophorous vacuole (PV).  The  bacteria relies on passive mechanisms of 
attachment and entry into host cells [47].  Lipid raft localized host integrin αVβ3 likely 
serves as the binding receptor for C. burnetii, and host phagocytosis is responsible for 
bacterial entry [48, 49].  Immediately following phagocytosis by the host cell, the 
bacterium is found within a tight fitting endosome [50].  This nascent PV sequentially 
acquires Rab5 and then Rab7, markers of early and late endosomes respectively. [51, 
52].  Further, Campoy et al. have reported that several endocytic SNARE proteins, which 
mediate the final stages of docking and fusion events between vesicle membranes, 
contribute to PV development, indicating that the PV matures through the canonical 
endocytic pathway [53]. 
 The mature PV is a large, modified phagolysosome that is distinct from other 
intracellular host or pathogen compartments [54].  The PV membrane is highly 
fusogenic, interacting with multiple host vesicle types, including endocytic, phagosomal, 
lysosomal, autophagic, as well as early, late, and recycling endosomal vesicles.  These 
fusion events contribute to the unique combination of protein markers and functional 
characteristics of the mature PV and allow for rapid expansion of the PV, which 
ultimately can occupy the majority of the cytoplasmic space within a cell [50].  
Interactions between the PV and host endocytic pathway have been shown by 
trafficking of the experimental fluid-phase markers fluorescein isothiocyanate-dextran 
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(FITC-dex) and Lucifer yellow (LY) to the PV lumen [55].  Vamp8, a SNARE protein that 
participates in homotypic fusion between late endosomes localizes to the PV early 
during infection at 1-12 hpi [53].  The PV is also decorated with Rab7, a late endosomal 
marker, throughout infection [56]. Furthermore, the endosomal compartment expands 
during C. burnetii infection, indicating that the bacteria is manipulating this pathway 
[57].  The PV also interacts with the autophagy pathway, as shown by LC3 localization to 
the PV membrane [56].  Additionally, induction of autophagy by amino acid starvation 
supports C. burnetii growth and PV expansion [58].  Rab1b, a marker of the anterograde 
transport pathway between the ER and the Golgi apparatus, is recruited to the PV 
membrane later than 6 hpi.  Additionally, knockdown of Rab1b by siRNA results in 
significantly smaller PVs and reduced C. burnetii growth [59].  Function and organization 
of the Golgi apparatus are required for normal formation and expansion of the PV.  This 
was demonstrated by studies on Sar1, a small GTPase involved in formation of COPII-
coated transport vesicles that bud from the ER.  Ectopic expression of a mutant form of 
Sar1 results in disassembly of the Golgi apparatus and significant decrease in the 
number of expanded, spacious PVs [59].  The Golgi membrane itself, defined by the 
protein and lipid markers GM130 and sphingomyelin derived from C6-NBD-ceramide are 
excluded from the C. burnetii PV [55, 60].  Finally, the nuclear protein, p62, is also 
excluded from the PV membrane, indicating that neither nuclear nor Golgi membranes 
directly contribute to that of the PV [60]. 
 The mature PV is a degradative organelle with many characteristics of true 
lysosomes.  The SNARE protein Vamp7, which participates in fusion between late 
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endosomes and lysosomes, localizes to the PV and is required for normal expansion of 
PV membrane [53].  The lysosomal proteins vATPase, Lamp1, and Lamp2 also localize to 
the PV membrane [55, 60]. PVs also contain active lysosomal enzymes including acid 
phosphatase and Cathepsin D [55, 61].  Howe et al. showed that treatment of infected 
cells with chloramphenicol results in collapse of this spacious vacuole, showing that 
bacterial protein synthesis is required for PV maintenance and that C. burnetii actively 
sustains PV size and function [62]. 
Intracellular lifecycle 
 The C. burnetii lifecycle is biphasic and involves the transition between two 
developmental morphotypes, the small cell variant (SCV) and the large cell variant (LCV), 
which differ in gene expression, structure, and growth rate (Figure 1).  The SCV is the 
small, electron dense, non-replicating form, which is almost completely metabolically 
inactive and resistant to many environmental insults.  The SCV can survive exposure to 
drying, heat, pressure, osmotic stress, sonication, UV light, and many disinfectants [63, 
64].  This dormant, resilient developmental stage is long-lived and can survive in 
extracellular environments, including contaminated soils and other fomites, for years 
[25, 65, 66].  Upon passive phagocytosis by a host cell, bacterial metabolism is induced 
by the acidic environment of the intracellular niche [67].  The SCV transitions to the LCV 
form during a two day-long lag phase beginning immediately after entry.  LCVs then 
divide in log phase for approximately four days before reaching stationary phase and 
beginning the transition to the SCV form [50].  The LCV is the only form that replicates 
within the host and is metabolically very active.  While both developmental forms are 
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Figure 1. Coxiella burnetii lifecycle in epithelial cells 
C. burnetii lifecycle in epithelial cells.  SCVs are passively phagocytosed 
and transition to LCVs during the first 2 days of infection.  Beginning 
approximately 2 dpi, the PV expands rapidly and LCVs replicate.  LCVs 
begin transitioning into SCVs approximately 6 dpi.  C. burnetii can 
remain within the living host cell for over a month and does not 
employ any known mechanisms to exit.  hpi hours post infection; dpi = 
days post infection; SCV = small cell variant (blue); LCV = large cell 
variant (red). 
28+ dpi
1 hpi
2 dpi
6 dpi 3 dpi
LCV
SCV
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capable of infecting host cells, it is likely that the SCV is the infectious form encountered 
during naturally occurring infection as this is the more stable extracellular state [68]. 
Type IVB Secretion System 
 The major C. burnetii virulence factor and method of manipulating host cells is the 
type IVB secretion system (T4BSS).  The T4BSS comprises a needle-like protein complex 
that translocates bacterial effector proteins across the inner and outer bacterial 
membrane as well as the PV membrane and into the host cell cytoplasm in order to 
manipulate various host cellular functions.  This system is conserved between Coxiella 
and Legionella sp., including the human pathogen, Legionella pneumophilia [69, 70].  A 
recent report suggests that the C. burnetii T4BSS may also be capable of translocating 
DNA, presenting another possible method of host cell manipulation by the bacteria [71].  
Mutations in the T4BSS protein components, DotA, DotB, and IcmD, have been shown to 
prevent translocation of effectors [72-74].  Characterization of these mutants show that 
the T4BSS is essential for growth and long-term survival of C. burnetii in host cells [75, 76].   
 More than 130 effector proteins are predicted to be translocated by the T4BSS.  
While the function of many of these proteins remains unknown, individually 
characterized effectors have been shown to target a variety of host functions including 
signal transduction [77], gene transcription [78], apoptosis [79], autophagy [58], and 
vesicular trafficking [74, 80] to support PV biogenesis and bacterial replication.  
Mutation of these secreted proteins individually has revealed intracellular growth 
defects, indicating that many serve important non-redundant functions during C. 
burnetii infection.  Analysis of C. burnetii genomes has revealed the presence of many 
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eukaryotic-like features, including F-box motifs and at least 13 proteins that contain 
ankyrin repeat domains [76, 81].  Most of these eukaryotic domain containing proteins 
are proven to be translocated by the T4BSS [79, 82].  It is hypothesized that these 
eukaryotic-like proteins were acquired by interdomain horizontal gene transfer [83, 84]. 
 Effector translocation relies on either an intrinsic signal sequence or shuttle 
proteins.  Most effectors contain a C-terminus E-block motif which functions as a 
secretory signal [85, 86].  A subset of effectors are also dependent upon the chaperone 
proteins, IcmW and IcmS, which facilitate interactions between effectors and the T4BSS 
complex [69].  To determine the timing of effector translocation, Newton et al. created 
reporter constructs encoding constitutively expressed effector proteins fused to a β-
lactamase enzyme lacking a signal sequence (BlaM).  Using a host cytoplasmic 
fluorescent reporter substrate that changes emission color when cleaved by the 
translocated BlaM enzyme allows fusion protein translocation to be detected by a color 
change from green to blue [74]. Translocation of effector proteins into the host cell 
cytoplasm occurs within 8-12 hours post infection in epithelial (HeLa) cells and within 1-
4 hours post infection in bone marrow-derived macrophages [51].  This approach does 
not reveal when specific effectors are translocated but it does, however, provide the 
first evidence that T4BSS-dependent translocation can occur early during infection. 
 
Cholesterol in eukaryotic cells 
 Development of the PV requires the rapid, coordinated acquisition and 
manipulation of host cell membranes.  Cholesterol is an important lipid component of 
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eukaryotic cell membranes and greatly influences membrane structure and function. 
Structurally, cholesterol affects membrane fluidity and permeability, with higher 
cholesterol levels resulting in increased membrane rigidity [87]. Due to these properties, 
the presence of cholesterol allows for increased ordering and discrete functional regions 
within membranes.  Cholesterol-rich micro-domains known as lipid rafts, for example, 
serve as specialized signaling platforms involved in signal transduction [88]. Further, 
intracellular cholesterol is a critical regulator of Golgi trafficking [89], endocytic 
trafficking [90], and intra-organelle membrane contact sites [91].   
 Cellular cholesterol is heterogeneously distributed between the various 
membranes of the cell (reviewed in [92]).  Between 60 and 90% of total cellular 
cholesterol resides in the plasma membrane, where it comprises 20-25% of the lipid 
molecules within that membrane.  Moderate amounts of cholesterol are also found in 
endocytic and trans-Golgi compartments, while less than 1% of total cellular cholesterol 
is found in the endoplasmic reticulum (ER) membrane [93].  When cholesterol 
accumulates in the ER membrane, the excess can be trafficked to other cell membranes 
or esterified and packaged into lipid storage organelles, lipid droplets [94].  
 Endogenous cholesterol is synthesized de novo in the ER and trafficked to the 
plasma membrane before distribution throughout the cell.  Exogenous cholesterol is 
acquired by receptor-mediated endocytosis of low density lipoproteins (LDL) or 
chylomicron remnants [95]. LDL particles are internalized by clathrin-mediated 
endocytosis and transported through the endocytic pathway to lysosomes, where 
cholesterol esters are hydrolyzed to free cholesterol for cellular use. Regardless of the 
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source, cholesterol can be transported throughout the cell by both vesicular and non-
vesicular (e.g., cholesterol transport proteins and membrane contact sites) trafficking 
pathways. 
 In addition to its role in membrane fluidity, cholesterol regulates membrane 
trafficking and signaling through a large family of sterol sensor and transfer proteins.  
Cholesterol distribution is controlled in part by sterol binding and transfer proteins, such 
as those in the human oxysterol binding protein (OSBP)-related protein family.  There 
are 12 mammalian OSBP-related protein family members, sharing two common 
domains: a highly conserved sterol-binding domain near the C-terminus and most also 
have a pleckstrin homology domain in the N-terminal half of the protein, which binds 
phosphatidylinositol lipids in membranes [96-98]. 
ORP1L 
 One member of this family, oxysterol-binding protein (OSBP)-related protein 1 
long (ORP1L), localizes to late endosomes and lysosomes (LEL).  This is confirmed by co-
localization with the small GTPases, Rab7 and Rab9, as well as Lamp1 [99, 100].  ORP1L 
has dual functions: 1) regulating cholesterol-dependent endosomal trafficking along 
microtubules and 2) formation of membrane contact sites (MCS) between late 
endosomes/lysosomes and the ER.  ORP1L undergoes cholesterol-dependent 
conformational changes that control whether endosomes interact with microtubules or 
with the ER (Figure 2; reviewed in [101]). When bound to cholesterol, ORP1L adopts a 
compact conformation (Figure 2A) with the N-terminal ankyrin repeats binding the 
Rab7/RILP (Rab-interacting lysosomal protein) complex and the C-terminal ORD (OSBP-
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related domain) binding cholesterol [99, 102].  When ORP1L is in this conformation, RILP 
is free to bind the homotypic fusion and protein sorting (HOPS)-tethering complex, 
which in turn binds the dynactin subunit p150Glued and dynein [103, 104].  Dynactin, the 
dynein activator complex, directly interacts with the motor protein dynein, increasing 
dynein motor processivity and facilitating the link between LEs and microtubules [105].  
This interaction with dynein facilitates minus end-directed transport of endosomes 
along microtubules [90, 106].  In the absence of cholesterol binding by ORD, ORP1L 
 
 
 
 
Figure 2. Cholesterol-dependent conformational changes in ORP1L 
ORP1L exists in two conformations on the endosomal membrane, 
interacting with Rab7/RILP in both conformations. (A) Cholesterol-
bound ORP1L takes on a condensed conformation, allowing RILP to 
interact with the HOPS and dynein motor complexes.  Together, 
these interactions result in minus-end directed movement of the 
endosome along microtubules toward the perinuclear space.  (B) 
When ORP1L is not bound to cholesterol it adopts an extended 
conformation, disrupting the interaction between RILP and the HOPS 
complex.  Instead, ORP1L forms membrane contact sites by binding 
VAP on the ER. 
cholesterol
VAP
Rab7
RILP
HOPS complex
dynein
ORP1L
A
endosome
ER
X
B
endosome
ER
X
15 
adopts an extended conformation (Figure 2B), allowing the ORP1L FFAT (two 
phenylalanines (FF) in an acidic tract) motif to interact with the resident ER protein VAP  
(VAMP-associated ER protein) [107].  As a result of binding to both the ER and LEL, 
ORP1L forms MCS between these two organelles and disrupts the protein complex 
mediating the association between Rab7/RILP and microtubules [102].  Related to its 
role in late endosome trafficking, ORP1L impacts transport of LDL cholesterol to the ER 
[108], multivesicular body (MVB) formation, and membrane protein degradation [109].  
These roles in lipid trafficking may additionally influence transcriptional regulation of 
cholesterol efflux genes [110].   
 Recent work from the Ridgway laboratory provides evidence that ORP1L is 
directly involved in transfer of cholesterol from LEL to the ER in cultured human cells.  
ORP1L null cells contain cholesterol enriched, perinuclear LELs, indicating that 
cholesterol taken up by the cell was retained within LELs [111].  This is consistent with 
the role of ORP1L in regulating endosome positioning reported by the Neefjes group 
[103, 112] (Figure 2A).  Cells lacking ORP1L also contained decreased esterified 
cholesterol relative to total cholesterol at the same time that cholesterol synthesis was 
elevated and LDL uptake was unchanged, indicating that less cholesterol is trafficked to 
the ER in these cells compared to control cells [111].   
 
Cholesterol homeostasis is a critical factor in C. burnetii infection 
 Multiple reports have implicated cholesterol as an important factor during C. 
burnetii infection. Howe and Heinzen showed that fillipin labels the PV membrane with 
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an intensity similar to that of the plasma membrane and the lipid raft protein flotillin-1 
localizes to the PV membrane [113].  Together, these findings indicated the PV 
membrane was rich in sterols, possibly including cholesterol. Further, multiple inhibitor 
studies indicated that cholesterol was important during C. burnetii infection.  Replication 
is inhibited in Chinese hamster ovary (CHO) cells treated with inhibitors of cholesterol 
metabolism [114].  Additionally, a screen of FDA-approved small molecule inhibitors 
revealed that disrupting cholesterol homeostasis broadly attenuates C. burnetii growth 
in human macrophage-like THP-1 cells [115].  Specifically, a subset of drugs was 
identified that alter intracellular cholesterol distribution in such a way that filipin 
labeling is increased on the plasma membrane and within endo-lysosomal vesicles.  57 
of 62 such compounds fully inhibited C. burnetii intracellular replication.  The same 
publication reported that knockdown of NPC1 by siRNA significantly attenuates bacterial 
growth [115].  NPC1 is a protein required for transferring cholesterol from the lumen of 
endolysosomes into the endolysosomal membrane so that it can be subsequently 
transferred to the ER [116].  The importance of NPC1 illustrates the possibility that 
cholesterol egress from the endolysosomal PV is critical to C. burnetii growth. 
 In order to explore the role of cholesterol during C. burnetii infection, Gilk et al. 
developed a cholesterol-free cell culture system using mouse embryonic fibroblasts 
(MEFs) in which DHCR24, the enzyme responsible for the final enzymatic step in 
cholesterol synthesis, was deleted, preventing the synthesis of endogenous cholesterol.  
This gene deletion results in cells that accumulate desmosterol in cell membranes in 
place of cholesterol.  This model serves as a powerful tool to explore the role of 
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cholesterol during C. burnetii infection when host cells are grown in the absence or 
presence of exogenous cholesterol [48]. Initial experiments showed no significant 
difference in C. burnetii replication in cells lacking both endogenous and exogenous 
cholesterol compared to cells grown in media containing a basal level of exogenous 
cholesterol [48].  Follow up experiments investigated the effect of adding additional 
exogenous cholesterol above basal levels to the cholesterol-negative MEFs.  This 
allowed investigators to measure the bacterial response to increasing cholesterol levels.  
Mulye et al. showed that increased cholesterol concentrations in host cells is 
detrimental to the C. burnetii. Bacterial growth is inhibited in a dose-dependent manner 
when host cells are cultured with increasing concentrations of exogenous cholesterol 
beyond basal levels.  Indeed, excess cholesterol leads to lysis of C. burnetii within the PV 
by a pH-dependent mechanism [117].  Multiple host-targeted cholesterol-altering drugs 
were shown to significantly reduce bacterial viability and result in PVs containing lysed 
bacteria.  These phenotypes could be rescued by co-treatment with bafilomycin, a drug 
which inhibits vacuolar ATPase (vATPase) thereby preventing lysosomal acidification.  
Furthermore, lytic PVs in infected cells with high cholesterol exhibited reduced 
fusogenicity with fluid-phase endocytic vesicles.  Mulye et al. measured this by 
quantifying the intensity of fluorescently labeled dextran that trafficked to PVs under 
various conditions, reporting that PVs with lysed bacteria acquired less dextran than PVs 
in cells with basal cholesterol levels [117].  Together with data showing that alteration 
of host cholesterol trafficking can impair bacterial growth, this suggests that C. burnetii 
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survival is inhibited and PV dynamics are altered by increased concentration and/or 
altered intracellular localization of cholesterol. 
C. burnetii targets cholesterol pathways 
 In addition to being sensitive to the concentration and localization of cholesterol 
within the host cell, C. burnetii infection results in changes in host cell cholesterol 
homeostasis.  Total intracellular cholesterol levels increase as much as 73% in Vero cells 
infected with C. burnetii [113].  This was initially hinted at by changes in gene expression 
observed in host cells upon infection which showed that genes involved in cholesterol 
efflux and storage are upregulated [118, 119].  Lipid droplets have been observed in 
association with the PV in infected primary human alveolar macrophages [120], and lipid 
droplet formation is induced in mouse alveolar macrophage cells upon infection [121].  
The evidence suggests the hypothesis that C. burnetii may manipulate host cell 
cholesterol levels and trafficking to promote its survival.  This evidence suggests that 
cholesterol is harmful to C. burnetii, and we hypothesize that the bacteria may be 
manipulating host cells in order to promote pathogenesis.   
ORP1L localizes to the C. burnetii PV membrane 
In order to avoid harmful exposure to cholesterol, we hypothesize that C. burnetii 
may manipulate host mechanisms controlling cholesterol levels in the PV membrane.  Given the 
cholesterol-dependent role of ORP1L in late endosome and lysosome trafficking, we 
hypothesized that ORP1L could be one such host target.  As a first investigatory step, we 
examined ORP1L localization during C. burnetii host cell infection.    ORP1L localization was 
observed in uninfected and infected HeLa cells expressing ORP1L fused to green fluorescent 
protein (GFP). By live cell microscopy, ORP1L-GFP localized to small vesicular structures in 
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uninfected cells (Figure 3A), consistent with published observations that ORP1L is found on
 
endosomes [110].  In C. burnetii-infected cells, ORP1L-GFP also localized to the C. burnetii PV 
[122] (Figure 3A).  N-terminal GFP-ORP1L exhibited the same localization pattern (Figure 3B), 
showing that the location of the GFP tag does not affect the localization of ORP1L.  
 
 
 
Figure 3. GFP-tagged ORP1L localizes to the C. burnetii PV 
membrane. 
Live cell confocal microscopy images of uninfected or infected HeLa 
cells expressing ORP1L-GFP (A).  In uninfected HeLa cells, ORP1L-GFP 
is found on vesicular structures (A, left).  ORP1L-GFP also localizes to 
the PV membrane (A, arrow) in HeLa cells infected for three days with 
C. burnetii expressing red fluorescent protein mCherry.  GFP-ORP1L 
also localizes to the C. burnetii PV (B, arrow).  Cell boundaries are 
shown with dotted white lines.    Scale bars = 10 µm. 
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Aims of this research 
 While high levels of cholesterol in the PV membrane has been shown to kill C. 
burnetii, the bacteria does successfully survive and replicate within host cells, which 
require cholesterol, during natural infection.   We hypothesize that C. burnetii 
manipulates cholesterol homeostasis to survive within the host, and ORP1L may be one 
host factor targeted by C. burnetii in order to reduce cholesterol levels in the PV. 
 
Aim 1:  Determine whether ORP1L localization to the PV occurs passively or is actively 
driven by C. burnetii.  If ORP1L is targeted by C. burnetii to manipulate host cholesterol, 
we hypothesize that ORP1L will be recruited to the PV by a bacteria-specific mechanism.  
In order to determine if this is the case, we will characterize the timing of ORP1L 
localization to the PV as well as the bacterial and host factors that affect ORP1L PV 
localization. 
 
Aim 2: Determine the role ORP1L may play while localized to the PV.  Multiple 
functions of ORP1L have been identified during normal endo-lysosomal function and we 
will investigate whether ORP1L functions in the same way during C. burnetii infection.  
We hypothesize that ORP1L may participate in cholesterol trafficking at membrane 
contact sites and/or control trafficking and fusion of the C. burnetii PV with endo-
lysosomal vesicles. 
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Chapter II. Methods 
 
Bacteria and mammalian cells 
 Coxiella burnetti Nine Mile Phase II (NMII; clone 4, RSA439) and mCherry-
expressing C. burnetti NMII [123] were purified from Vero cells (African green monkey 
kidney epithelial cells, ATCC CCL-81; American Type Culture Collection, ATCC, Manassas, 
VA) and stored as previously described [124].  For experiments examining T4BSS-
dependent recruitment of ORP1L, NMII and the icmD mutant [73] were grown for 4 days 
in ACCM-2, washed twice with PBS (phosphate buffered saline), and stored as previously 
described [125].  The multiplicity of infection (MOI) was optimized for each bacteria 
stock for <1 internalized bacterium per cell.  Vero and human cervical epithelial cells 
(HeLa; ATCC CCL-2) were maintained in RPMI 1640 medium (Corning, New York, NY) 
containing 10% fetal bovine serum (FBS) (Atlanta Biologicals, Norcross, GA) at 37°C and 
5% CO2.  Human embryonic kidney epithelial cells (293T, ATCC CRL-326) were 
maintained in DMEM medium (Corning) containing 10% FBS. 
 
Generation of plasmids 
ORP1L-GFP constructs 
 Full length, wild type ORP1L-GFP was a generous gift of J. Neefjes (Netherlands 
Cancer Institute).  This plasmid contains ORP1L amplified from human cDNA.  For 
construction of ORP1L domain GFP constructs, ORP1L domains [100] were amplified 
using full length ORP1L-GFP as a template and cloned into the BsrG1 site of 
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pcDNA6.2/N-EmeraldGFP using In-Fusion (Takara Bio USA, Mountain View, California).  
The pcDNA6.2/N-ORP1L-EmeraldGFP construct that we created is referred to as 
“ORP1L-GFP” in this work.  The following primer combinations were used:  Full length 
ORP1L (amino acids (AA) 1-950) = ORP1L-1-F and ORP1L-950-R; ORD (AA 510-950) = 
ORP1L-510-F and ORP1L-950-R; PH (AA 211-345) = ORP1L-211-F and ORP1L-345-R; Ank-
PH (AA 1-408) = ORP1L-1-F and ORP1L-408-R; Ank (AA 1-237) = OFP1L-1-F and ORP1L-
237-R; ∆Ank (AA 211-950) = ORP1L-211-F and ORP1L-1-R.  FFAT mutant (D478A) was 
generated using site directed mutagenesis with primers ORP1L-D478A-F and ORP1L-
D478A-R according to the manufacturer’s directions (Takara Bio USA).  Primer 
sequences are in Table 1. 
ORP1L FRET constructs 
 Turquoise-Venus-FRET-10 plasmid was a gift from Michael Davidson (Addgene 
plasmid #58158).  To make the empty FRET vector plasmid (pcDNA6.2-mTurquoise-
mVenus) Venus-Turquoise was amplified from Turquoise-Venus-FRET-10 plasmid and 
cloned into the BamHI and AgeI sites of pcDNA6.2-N-mCherry-DEST by In-Fusion, 
replacing the mCherry and att insertion sites.  Full-length or ΔORD ORP1L was amplified 
from ORP1L-GFP and cloned into the AgeI site of the pcDNA6.2-mTurquoise-mVenus by 
In-Fusion.  The following primer pairs were used: full-length (AA 1-950) = ORP1L-1-FRET-
F and ORP1L-950-FRET-R; and ΔORD (AA 1-514) = SG060 and SG061.  Primer sequences 
are in Table 1. 
23 
BioEASE constructs 
 ORP1L was amplified from ORP1L-GFP and cloned into BsrGI-digested pcDNA6.2-
N-BioEASE-DEST by In-Fusion.  The following primer combinations were used: Full-length 
ORP1L (AA 1-950) = SG107 and SG110; Ank (AA 1-237) = SG107 and SG 109; ΔAnk (AA 
211-950) = SG108 and SG110.  Primer sequences are in Table 1.  These primers amplify 
the same ORP1L sequences as the corresponding GFP constructs, but contain sequences 
that are unique to the pcDNA6.2-N-BioEase-DEST plasmid vector. 
mCherry-CBU_0352 mammalian expression construct 
Genomic DNA was isolated from C. burnetii anexic culture grown for 4 days in ACCM- 2 
media using the DNeasy UltraClean Microbial Kit (12224; Qiagen, Carlsbad, CA).  The 
cbu0352 coding region was amplified with primers SG350 and SG351 (sequences in 
Table 1) from C. burnetii NMII genomic DNA and cloned into BsrGI-digested pcDNA6.2-
N-mCherry-DEST using In-Fusion. 
CyaA constructs 
cbu0352 was amplified with primers SG224 and SG225 (sequences in Table 1) from C. 
burnetii NMII genomic DNA and cloned into the SalI site of pJB-Kan-CyaA or pJB-CAT-
CyaA using In-Fusion cloning.   
cbu0352 suicide plasmid 
Following a previously published cloning strategy [126], a two-step process was used to 
construct the suicide plasmid.  The genomic regions (approximately 2000 bp) 
immediately up and downstream of the cbu0352 locus were amplified from C. burnetii 
NMII genomic DNA and cloned into BamHI- and SalI-digested pJC-CAT vector by 3-way 
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In-Fusion, introducing a PstI restriction site between the two fragments.  Next, the 
LysCA cassette was amplified from the pJC-CAT-LoxP-LysCA-LoxP plasmid and cloned 
into the PstI site in the intermediate plasmid.  The following primer pairs were used:  
cbu0352 5’ flanking region (2047 base pairs (BP)) = SG259 and SG260; cbu0352 3’ 
flanking region (2000 BP) = SG261 and SG262; and LysCA cassette = SG257 and SG256. 
Primer sequences are in Table 1. 
FLAG-tagged CBU_0352 constructs 
To make the N-terminal fusion, cbu0352 was amplified with primers SG240 and SG241 
from C. burnetii NMII genomic DNA and cloned into the SalI site of pJB-Kan-3xFLAG.  For 
the C-terminal fusion, cbu0352 was amplified with primers SG242 and SG243 
(sequences in Table 1) and cloned into the PstI site of the same plasmid. 
sgRNA constructs for CRISPR 
The lentiCRISPRv2 plasmid was a gift from Feng Zhang (Addgene plasmid # 52961). 
ORP1L small guiding RNAs (sgRNAs) were designed using the CRISPR Design tool (Zhang 
Lab, MIT, 2015) and cloned into lentiCRISPRv2 with a protocol modified from the Zhang 
Lab [127]. Phosphorylated DNA oligonucleotide pairs were annealed and cloned into 
BsmBI-digested lentiCRISPRv2 using T4 Ligase (ThermoFisher Scientific, Waltham, MA).  
The following oligonucleotide pairs were used:  ORP1LsgRNA1 = (SG289 and SG290); 
ORP1LsgRNA2 = (SG291 and SG292); ORP1LsgRNA3 = (SG293 and SG294).  Primer 
sequences are in Table 1. 
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2xHA-MetRSNLL construct 
pAM1, containing the mutant E. coli gene, MetRSNLL, was a gift from David Tirrell 
(Addgene plasmid # 51401, [128]).  MetRSNLL contains three mutant residues in the 
methionine (Met)-binding pocket of the MetRS enzyme (L13N, Y260L, and H301L), 
resulting in an enzyme that activates azidonorleucine (Anl) in place of methionine [129].  
MetRSNLL was amplified from pAM1 with primers SG038 and SG039 and cloned into the 
pCR-Blunt II-TOPO plasmid using the Zero Blunt TOPO PCR Cloning Kit (450245, 
Invitrogen) to create the intermediate pCR-Blunt II-TOPO-MetRSNLL.  MetRSNLL was 
isolated from this intermediate plasmid by SalI digestion and ligated into the SalI site of 
pJB-CAT-2xHA with T4 Ligase to create an N-terminally HA-tagged MetRSNLL driven by 
p1169, a constitutively active C. burnetii promotor. 
 
Mammalian cell transfection and immunofluorescence assay (IFA) 
 HeLa cells (2x104 cells per well of a 24 well plate) were plated on acid-washed 
glass coverslips and simultaneously transfected with 0.4 μg of plasmid DNA with 
Fugene6 (Promega, Madison, WI) according to the manufacturers reverse transfection 
protocol.  Plasmid stocks for transfection were prepared using the Endotoxin-free 
Maxiprep Kit (MilliporeSigma, Saint Louis, MO). Approximately 24 hours post-
transfection, cells were infected with C. burnetii in 0.25 mL RPMI with 10% FBS for two 
hours at 37°C, 5% CO2, washed extensively with PBS, and incubated in RPMI+FBS.  At the 
indicated times post-infection, the cells were washed 3x in PBS and fixed with 4% 
paraformaldehyde (PFA) in PBS for 15 minutes.  Cells were permeabilized and blocked 
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by treatment with 0.1% saponin/1% bovine serum albumin (BSA)/PBS for 15 minutes, 
and then incubated with mouse anti-CD63 (556019; BD Biosciences, San Jose, CA) or 
rabbit anti-Lamp1 (ab24170; Abcam, Cambridge, MA), and guinea pig anti-C. burnetii 
serum [130] for one hour in saponin/BSA/PBS.  Following incubation with AlexaFluor 
secondary antibodies (Invitrogen, Carlsbad, CA) in saponin/BSA/PBS, coverslips were 
mounted on glass slides using ProLong Gold with DAPI (Invitrogen), allowed to dry 
overnight, and visualized using a Leica inverted DMI6000B microscope (63X oil 
objective).  Images were captured using a DFC365FX camera with Leica Application Suite 
X software (version1.5.0) and formatted for publication using ImageJ software (NIH,  
Bethesda, MD). 
 
Live cell microscopy 
 For localization of ORP1L domain GFP constructs, HeLa cells were transfected 
and infected with mCherry-expressing C. burnetii as described above.  At 3 days post 
infection, the cells were collected, plated in ibidi μ-Dishes (ibidi, Verona, Wisconsin), and 
visualized live on the Leica microscope described above. 
 For ER localization studies, HeLa cells were transfected with mCherry-CBU_0352 
or the mCherry empty vector (EV), as above. After 48 hours, cells were transduced with 
the ER marker KDEL-GFP CellLights BacMam, expressing GFP fused to the ER signal 
sequence of calreticulin and the ER retention signal amino acid sequence, KDEL, 
(ThermoFisher Scientific, C10590, MOI of 10) and incubated overnight.  Cells were 
trypsonized, re-plated on ibidi μ-dish, and allowed to adhere for several hours before 
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being visualized on Nikon Eclipse Tί inverted light microscope (Nikon Instruments Inc., 
Melville, NY) with a 100X objective.  Images were captured with ORCA-Flash 4.0 LT PLUS 
Digital CMOS Camera (Hamamatsu Corporation, Bridgewater, NJ) and NIS Elements BR 
Analysis software (Nikon Instrument Inc.). 
 
Recruitment and PV measurements 
 Fixed cells were visualized with the Leica microscopy described above, and CD63-
positive or Lamp1-positive PVs were visually scored as GFP-positive or negative to 
determine ORP1L-GFP recruitment. PVs with co-localization between the PV marker 
(CD63 or Lamp1) and protein of interest were scored as positive. Images were captured 
using a DFC365FX camera with Leica Application Suite X software (version 1.5.0).  For 
recruitment of ORP1L to wild type and IcmD mutant PVs, 15-20 PVs were scored for 
each of four independent experiments.  For PV size measurements, each PV was imaged 
and the cross-sectional area at the widest part of the PV was measured with ImageJ 
software.   
 
siRNA knockdown in HeLa cells 
 ORP1L and non-targeting ON-TARGETplus SMARTpool siRNA duplexes were 
obtained from GE Dharmacon (Lafayette, CO).  HeLa cells (1.2x105 cells) were 
transfected with 50 nM siRNA in 6 well plates using DharmaFECT 1 according to the 
manufacturer’s reverse transfection protocol (GE Dharmacon).  Two days later, the cells 
were infected with C. burnetii for one hour as described above, trypsinized, and 
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transfected a second time with 50 nM siRNA in 24 well plates (2.5x104 cells per well).  At 
the given time points, wells were processed for either immunoblotting, FFU growth 
assay, or IFA. Single target ORP1L siRNA (UGCCAGUGCCGGAUUCUGAdTdT, [103]) was 
obtained from MilliporeSigma.  Cells were transfected with 50 nM siRNA.  For 
immunoblotting, cells were harvested in 2% sodium dodecyl sulfate (SDS) in tris-
buffered saline (TBS).  Total protein (15 µg) was separated by SDS-PAGE, transferred to 
polyvinylidene difluoride (PVDF) membrane (EMD Millipore, Kankakee, IL), blocked in 
Odyssey Blocking Buffer (P/N 927-40000, LI-COR, Lincoln, NE) diluted 1:1 with PBS, and 
probed with rabbit anti-ORP1L (Abcam 131165) or rabbit anti-VapB (Abcam ab10113) 
diluted 1:1000 in 1% BSA/PBS, and mouse anti-GAPDH (ThermoFisher MA5-15738), 
diluted 1:4000 in BSA/PBS, followed by incubation with LI-COR infrared secondary 
antibodies (ThermoFisher) diluted 1:10,000 in Odyssey Blocking Buffer/PBS.  Blots were 
imaged using an Odyssey Tc Imager (LI-COR) and bands quantitated using Image Studio 
Software (LI-COR).  ORP1L or VAP knockdown efficiency was calculated by first 
normalizing to GAPDH, and then to the non-targeting control. 
 For Rab7 and RILP localization experiments, 2.5x104 HeLa cells were transfected 
with 50nM ORP1L or non-targeting ON-TARGETplus SMARTpool siRNA duplexes in 24-
well plates.  24 hours later, cells were transfected with EGFP-Rab7A or RILP-GFP 
plasmids using standard Fugene6 transfection protocol and incubated overnight.  The 
next day, double-transfected cells were infected with mCherry-expressing C. burnetii.  3 
days post infection, cells were fixed and stained for IFA.  EGFP-Rab7A was a gift from 
Qing Zhong (Addgene plasmid # 28047 [131]). 
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Fluorescent Infection Foci Forming Unit (FFU) assay 
 To quantify bacterial growth in HeLa cells, FFU assays were performed as 
previously described [50].  Briefly, bacteria were released from infected HeLa cells by 
incubating for 5 minutes in sterile water and pipetting up and down, followed by serial 
dilutions in 2% RPMI and addition to Vero cell monolayers in 24-well plates.  After 5 
days, the cells were fixed with methanol and visualized with Hoechst 33342 Solution 
(ThermoFisher), and rabbit anti-C. burnetii antibody followed by goat anti-rabbbit Alexa 
Flour 488 secondary antibody.  Fluorescent foci were visualized using an EVOS FL Auto 
Imaging System (ThermoFisher) and counted using ImageJ.  Each experiment was done 
in duplicate. 
 
Lentivirus preparation and infection  
 To generate lentivirus particles, HEK293T cells were plated in a 6-well plate at 
1x106 cells per well and simultaneously transfected using Fugene6 with packaging and 
shRNA plasmids: 300ng pCMV-VSV-G, 250ng pRSV-Rev, 500ng pMDLg/pRRE, 1000ng 
shRNA targeting plasmid.  At 24, 48, and 72 hours post transfection, the supernatant 
was collected, pooled, filtered through a .22μM syringe filter, and concentrated 
approximately 10X using Lenti-X Concentrator (Takara Bio USA) according to the 
manufacturer’s instructions.  Concentrated lentivirus was aliquoted and stored at -80⁰C.  
Lentivirus concentration in these preparations was quantified using the Lent-X qRT-PCR 
Titration Kit (Takara Bio USA).   
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C. burnetii transformation, selection, and anexic culture 
 For each transformation, 1 T75 flask containing 20mL of C. burnetii anexic culture 
was grown for 4 days and pelleted at 19,000 xg for 15 minutes. Bacteria was washed 
once in 30 mL cold 10% glycerol, pelleted as above, and suspended in 100 µL cold 10% 
glycerol.  50 µL of bacteria was mixed with 10 μg of plasmid DNA, transferred to an ice 
cold 0.1 cm electroporation cuvette and electroporated at 1.8 kV, 500 ῼ, 25 µF.  
Immediately after electroporation, 950µL serum-free RPMI was added and mixed by 
pipetting.  100 µL of transformation mix was added to 6mL media in a T25 flask and 
incubated 24-48 hours at 5% CO2, 2.5% O2 before adding appropriate antibiotics for 
selection (Chloramphenicol at 3 µL/mL; Kanamycin at 275 µg/mL).  When the culture 
became turbid (6-12 days, depending on the transfection efficiency), it was passaged to 
new T25 flasks with 6mL media at several inocula (50 µL, 100 µL, or 200 µL passed).  The 
most dilute initial culture that became turbid within 5-7 days was plated to isolate single 
clones by limiting dilution in a 96-well plate.  6 days later, wells with single clones were 
identified and allowed to grow 4 additional days before expanding by transferring the 
entire culture to 24-well plate wells containing 500 µL media.   
Data analysis 
 Image processing and PV size measurements were done with ImageJ software 
(W.S. Rasband, National Institutes of Health, Bethesda, MD).  Statistical analyses were 
performed using appropriate tests in Prism (GraphPad Software, Inc., La Jolla, CA). 
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Table 1. Primers used in this study 
Primer Name Sequence 
ORP1L-1-F ATGGACGAGCTGTACAAGATGAACACAGAAGCGGAGCAAC 
ORP1L-1-FRET-F TCAGATCCCCACCGGTTATGAACACAGAAGCGGAGCAAC 
ORP1L-950-
FRET-R 
TGGTGGCGACCGGTGGATAAATGTCAATAAATGTCAGGCAAATTG 
ORP1L-211-F ATGGACGAGCTGTACAAGAAACCTCTTGACCTTGCCCAGGGTG 
ORP1L-510-F 
ATGGACGAGCTGTACAAGAGAAAACACAGAATGTCCGAAGAAAA
AGAC 
ORP1L-237-R AATATCACTCTGTACATTATCGTTTCAATGCTTTGTAGATGACC 
ORP1L-408-R AATATCACTCTGTACATTAAGAAGCTTCTGAGACAACTTCAAC 
ORP1L-950-R AATATCACTCTGTACATTAATAAATGTCAGGCAAATTGAAG 
ORP1L-D478A-F GCGAGGACGAGTTCTATGCTGCGCTGTCAGATTCCGA 
ORP1L-D478A-R TCGGAATCTGACAGCGCAGCATAGAACTCGTCCTCGC 
SG038 AGATTACGCTGTCGACATGACTCAAGTCGCGAAGAAAATTCTGG 
SG039 GCATGCCTCAGTCGACCCAGTGCTTCAACCTGCC 
SG060 TCAGATCCCCACCGGTTATGAACACAGAAGCGGAGCAAC 
SG061 CATGGTGGCGACCGGTGGCATTCTGTGTTTTCTACTGCCC 
SG107 ATCAACAAGTTTGTACATGAACACAGAAGCGGAGCAAC 
SG108 ATCAACACTTTGTACAAGAAACCTCTTGACCTTGCCCAGG 
SG109 TCAACCACTTTGTACAATATCGTTTCAATGCTTTGTAGATGAC 
SG110 TCAACCACTTTGTACAATAAATGTCAGGCAAATTGAAG 
SG220 TCATAAACACAGCTACGGGTTTGG 
SG221 CTTTCACACCTTCAAAACGGACC 
SG224 TTCCGGCTATGTCGACATGCTTATAACAAGGTGTACATTCTTC 
SG225 GCATGCCTCAGTCGATTAAAGCTTATAACAAGGTGTACATTCTTC 
SG240 CATGCCTCAGTCGACTTAAAGCTTATAACAAGGTGTACATTC 
SG241 CGATGACAAGGTCGACATGCATACTCACGAACATC 
SG242 TGTAGTCCATCTGCAGAAGCTTATAACAAGGTGTACATTC 
SG243 CATGAAGGAGGCTGCAGATGCATACTCACGAACATCATC 
SG257 TCCCAGGCATTTATACCGCCAAC 
 
SG258 TCCGTTGAGAGTATGCCGCTACC 
SG259 GTGGCTCTGCTTGAAACACTAGTGC 
SG260 AATTGCAAACACTGGGGCCTATGG 
SG261 ACCAGCTAATGGAGACAGTCATACTGG 
SG262 TCACCCTTAAAACTCAGCGCTTGC 
SG350 ATGGATGAGCTGTACATGCATACTCACGAACATCATCATCA 
SG351 
TCAACCACTTTGTACCTTTGTTATTAAAGCTTATAACAAGGTGTACA
TTCTTCA 
SG289 CACCGTGTGTGCATAACATCATCGT 
SG290 AAACACGATGATGTTATGCACACAC 
SG291 CACCGCTGAGATGAGCCTAAACCCA 
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Table 1, continued 
SG292 AAACTGGGTTTAGGCTCATCTCAGC 
SG293 CACCGGCATGGAATGCACTGATTGG 
SG294 AAACCCAATCAGTGCATTCCATGCCGGTC 
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Chapter III. ORP1L is specifically recruited to the PV by C. burnetii 
 
ORP1L co-localizes with PV marker CD63 
 ORP1L was previously localized to the PV membrane by live cell imaging.  To 
confirm this finding, HeLa cells transfected with ORP1L-GFP and infected with wild type 
C. burnetii were analyzed by IFA and stained for CD63.  CD63, also known as lysosomal-
associated membrane protein 3 (Lamp3), is a lysosome and PV marker used to delineate 
the C. burnetii PV membrane [132].  ORP1L clearly co-localizes with CD63 (Figure 4), 
confirming that ORP1L indeed localizes to the PV membrane during C. burnetii infection. 
 
ORP1L ankyrin repeats are necessary and sufficient to localize GFP to the PV membrane 
ORP1L contains multiple domains responsible for both protein-protein and 
protein-lipid interactions (Figure 5A).  Three N-terminal ankyrin repeats interact with 
the small GTPase Rab7 [133].  ORP1L association with the ER is mediated through an 
FFAT motif that binds the ER protein VAP [102].  The pleckstrin homology (PH) domain 
binds with low affinity and high specificity to the signaling lipids PI(3,4)P2 and PI(3,4,5)P3 
[100], while the C-terminal ORD binds cholesterol and several oxysterol species [134, 
135].  To identify the ORP1L domain(s) responsible for PV localization, we generated 
GFP fusions of the ORP1L domains and assessed their localization using live cell imaging 
of C. burnetii-infected cells (Figure 5B, C).  Like wild type ORP1L, ORP1L with a mutated 
FFAT motif localized to the PV.  Removal of the cholesterol-binding domain (ΔORD) did 
not alter the PV localization and the ORD domain by itself was cytoplasmic, indicating 
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cholesterol is not significantly involved in ORP1L PV localization.  In addition to 
cholesterol, the signaling lipids PI(3,4)P2 and PI(3,4,5)P3 also appear to be insufficient for 
PV localization, as GFP fusions of the phosphoinositide-binding PH domain was also 
 
 
Figure 4. ORP1L co-localizes with CD63 on the PV membrane 
Fixed immunofluorescence microscopy images of uninfected or 
infected HeLa cells expressing ORP1L-GFP.  ORP1L-GFP localizes to the 
PV membrane in HeLa cells infected for three days with wild type C. 
burnetii.  Cell boundary is shown with dotted white line.  CD63 is a 
marker for the PV membrane.  Scale bars = 10 µm. 
 
 
 
35 
 
 
36 
cytoplasmic with no PV association.  In contrast, PV localization was observed for both 
the ORP1L ankyrin repeat domain along with the PH domain (Ank-PH) and the ORP1L 
ankyrin repeat domain alone (Ank).  To determine if the ankyrin repeats are required for 
PV association, we generated an ORP1L ankyrin truncation mutant (ΔAnk).  ΔAnk-GFP 
did not localize to the PV and was cytoplasmic, demonstrating that the N-terminal 
ankyrin repeats are necessary and sufficient for ORP1L association with the PV.  Further, 
these data show that protein-protein interactions, and not protein-lipid interactions, are 
primarily responsible for ORP1L PV localization.  
Active C. burnetii Type IVB Secretion System is required for ORP1L recruitment 
The C. burnetii T4BSS transports bacterial effector proteins across the PV 
membrane and into the host cell cytoplasm where they manipulate host cell functions 
Figure 5. Ankyrin repeat domains are necessary and sufficient to 
target ORP1L to the PV 
(A) Stick diagram of ORP1L protein domains. ANK = ankyrin repeats 
(black), PH = plekstrin homology domain (stripe), CC = coiled-coil 
domain (white), FFAT = two phenylalanines in an acidic tract 
(gray), ORD = OSBP-related ligand binding domain (dots). Numbers 
represent amino acid position.  (B) HeLa cells were transfected 
with C-terminal GFP constructs and infected with mCherry-
expressing C. burnetii.  Domain constructs are represented below 
each image.  At 3 days post infection, live cells were imaged by 
wide field fluorescence microscopy.  FFAT mutant (D478A) 
(magenta), Ank-PH, and Ank localize to the PV membrane, while 
ORD, Δ Ank, and PH remain cytoplasmic without PV membrane 
localization. Green = ORP1L-GFP, Red = mCherry-C. burnetii.  Scale 
bar = 10 µm.  (C) Quantification of PV localization of ORP1L domain 
constructs.  Shown are the results from two independent 
experiments, with at least 30 PVs per condition per experiment.  
Error bars represent SEM. 
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Figure 6. ORP1L PV localization is T4BSS-dependent 
Light microscopy images of HeLa cells transfected with ORP1L-GFP 
and then infected with C. burnetii for 2 days (A). ORP1L-GFP is 
recruited to the PV of wild type (top) but not IcmD mutant (bottom) 
bacteria. Green = ORP1L-GFP, Red = Lamp1, Gray = C. burnetii, Blue = 
DAPI.  The PV (circled) is shown magnified with individual fluorescent 
channels.  Scale bar = 10 µm.  (B) The number of ORP1L-positive PVs 
was quantified over a 72 hour time course of infection in HeLa cells 
infected with wild type (solid) or IcmD mutant (dashed) C. burnetii.  
Cells were transfected with ORP1L-GFP, infected, stained for C. 
burnetii and Lamp1, and visually scored for the presence or absence 
of ORP1L on the PV.  Each data point represents the average of 3 or 4 
experiments, with at least 20 PVs counted per experiment.  Error 
bars represent standard error of the mean (SEM).  Means for each 
condition within a timepoint were compared by the Holm-Sidak 
method of multiple t-tests. * = p <0.01. 
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such as vesicular trafficking and apoptosis (reviewed in [136]).  T4BSS effector proteins 
recruit several host cell proteins to the PV including clathrin [137] and LC3 [138].  To 
determine if the T4BSS or secreted effectors are involved in ORP1L PV localization, we 
examined ORP1L-GFP-expressing cells infected with either wild type C. burnetii or a C. 
burnetii mutant lacking IcmD, an essential component of the T4BSS [73] .  Cells were 
fixed and stained for C. burnetii and Lamp1, a lysosomal protein that also serves as a 
marker for the C. burnetii PV.  Unlike PVs harboring wild type bacteria, ORP1L-GFP did 
not localize to PVs containing the IcmD mutant (Figure 6A).  When quantified, over 85% 
of wild type PVs were ORP1L-positive by 24 hours post infection, with nearly 95% being 
positive by 48 hours (Figure 6B).  In contrast, less than 10% of the IcmD-mutant PVs 
were positive at any point during a 72 hour infection, demonstrating that the T4BSS is 
required for ORP1L localization to the C. burnetii PV. 
 
ORP1L is recruited early during infection, prior to PV expansion 
T4BSS-dependent localization of ORP1L to the PV could occur either through 
fusion with endosomes, or through direct recruitment by a PV-associated protein.  
ORP1L does not contain transmembrane domains, and membrane association requires 
binding to membrane proteins and lipids.  We therefore hypothesized that ORP1L 
interacts with the PV by protein-protein or protein-lipid interactions, and is not 
delivered through membrane fusion events during PV expansion.  To test this, we 
assessed the timing of PV expansion relative to ORP1L PV localization.  To determine 
when PV expansion occurs in HeLa cells, we measured PVs harboring either wild type or 
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Figure 7. ORP1L is recruited to the PV prior to significant expansion 
Measurements of PV size shows that PVs harboring wild type bacteria 
expand between 24 and 48 hours, while IcmD mutant PVs do not 
expand (A).  HeLa cells, untransfected or expressing ORP1L-GFP, were 
infected with either wild type C. burnetii or the IcmD mutant.  At the 
indicated times, the cells were fixed, stained for C. burnetii and CD63, 
and the PVs measured using ImageJ.  PVs harboring wild type bacteria 
expanded between 24 and 48 hours, while IcmD PVs did not expand.  
Shown are individual PV measurements from three separate 
experiments, with at least 20 PVs per timepoint per experiment. Bars 
represent mean ± SEM. (B) Comparison of ORP1L localization 
compared to PV expansion; ORP1L localizes to the PV 12 hours prior to 
significant expansion of wild type PVs (top).  Error bars represent SEM. 
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IcmD mutant bacteria during a 72 hour infection time course (Figure 7A).  PVs harboring 
IcmD mutant bacteria never expanded although a very small amount of replication was 
observed.  This is consistent with the role of the T4BSS in PV fusion and expansion [73, 
80].  For wild type bacteria, a small amount of expansion was observed by 24 hours, 
with the vast majority of PVs expanding between 24 and 48 hours.  At 48 hours post 
infection, there was a small but statistically significant difference in PV size between 
untransfected and ORP1L-GFP transfected cells (Figure 8).  However, the timing of 
expansion was identical, suggesting that ectopic expression of ORP1L-GFP does not 
affect the overall timing of expansion.  When PV size was compared to ORP1L PV 
localization in wild type PVs, ORP1L was present on the PV prior to significant expansion 
and therefore before significant fusion of additional vesicles with the PV (Figure 7B).  
Furthermore, ORP1L recruitment was independent of PV size, as wild type ORP1L-
positive PVs were nearly identical in size to IcmD mutant ORP1L-negative PVs at early 
time points (Figure 7A).  Based on these data, we hypothesize ORP1L is directly recruited 
by a PV membrane-localized protein prior to PV expansion.  
 
ORP1L is recruited independently of another endosomal PV marker 
 ORP1L binds Rab7 [100], a late-endosomal protein that also localizes to the PV 
and plays a role, though the mechanism remains unknown, in PV biogenesis [56, 139].  
We hypothesized that the lack of ORP1L on IcmD mutant PVs could be due to the 
absence of a binding partner, Rab7.  We observed, however, that Rab7 localizes to both 
wildtype and IcmD mutant PVs, whereas ORP1L only localizes to wild type PVs (Figure 
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6B).  Moreover, the kinetics of Rab7 localization was nearly identical in the first 24 
hours, at which time nearly 90% of both wild type and IcmD mutant PVs were Rab7 
positive (Figure 9).  Interestingly, PVs harboring the IcmD mutant began to lose Rab7 
localization after 24 hours, suggesting the T4BSS is necessary to retain or acquire 
additional Rab7 at later time points.  This data indicates, at least during early PV 
development, ORP1L is recruited independently from Rab7. 
 
 
 
 
 
Figure 8. PV size in untransfected and ORP1L-GFP expressing cells 
At 48 hours post infection, wild type PVs in cells ectopically expressing 
ORP1L-GFP are smaller than untransfected cells.  Error bars represent 
SEM.  Means were compared by ordinary one-way ANOVA with 
Sidak’s multiple comparisons tests.  ** = p <0.01. 
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Tn235 C. burnetii exhibits a decrease in ORP1L recruitment 
 In order to investigate which C. burnetii effector protein or proteins are involved 
in recruiting ORP1L to the PV, we utilized mutants with transposon insertions in genes 
encoding known or predicted T4BSS effector proteins [140].   These mutants also 
 
 
Figure 9. ORP1L is recruited to the PV independently of Rab7 
The number of Rab7-positive PVs was quantified over a 72 hour time 
course of infection in HeLa cells infected with wild type (solid) or IcmD 
mutant (dashed) C. burnetii.  Cells were transfected with Rab7-GFP, 
infected, stained by immunofluorescence for C. burnetii and Lamp1, 
and visually scored for the presence or absence of Rab7 on the PV.  
(Same procedure as for ORP1L in Each data point represents the mean 
from 3 or 4 independent experiments, with 20 PVs counted per 
experiment.  Error bars represent standard deviation.  Data from each 
condition within a timepoint was compared by the Holm-Sidak 
method of multiple t-tests.  * = p-value <0.05. 
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express GFP.  IcmD mutant bacteria, which we have previously shown does not recruit 
ORP1L to the PV (Figure 6B), were a negative control.  HeLa cells transfected with 
ORP1L-mCherry were infected with wild type or mutant C. burnetii, allowed to grow for 
3 days and processed for IFA.  PVs were scored as mCherry positive or negative and as 
expected, greater than 95% of wild type PVs were ORP1L-positive and fewer than 5% of 
IcmD mutant PVs were ORP1L-mCherry positive (Figure 10A).  Interestingly, disruption 
of the IcmS gene did not disrupt ORP1L recruitment.  IcmS encodes for half of the 
IcmSW chaperone which is required for secretion of a subset of T4BSS effector [69, 141].  
This mutant is predicted to be deficient in the secretion of several effector proteins, yet 
it does not significantly affect ORP1L recruitment, supporting the hypothesis that ORP1L 
recruitment is the result of the action of a specific effector and not general T4BSS 
function.  One effector mutant was significantly deficient in ORP1L recruitment to the 
PV.  Only 50% of mutant 235 PVs were ORP1L-positive at 3 days post infection (Figure 
10), indicating that the transposon in mutant 235 disrupted a gene involved in ORP1L 
recruitment. 
 Once we identified a mutant that was deficient in ORP1L recruitment to the PV, 
we next sought to confirm the location of the transposon within the bacterial genome 
and determine whether we had a clonal population.  To this end, we designed a primer 
set centered about the genomic locus where the transposon was reported to have 
inserted in this strain, nt 457 of the cbu0352 gene [140] (Figure 11A).  Genomic DNA was 
isolated from mutant 235 or wild type C. burnetii and the cbu0352 locus was amplified 
by PCR, revealing that both the wild type and mutant cbu0352 locus was present in the 
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mutant 235 stock.  This could indicate that either a gene duplication event has occurred, 
resulting in multiple copies of the cbu0352 being present, or that the strain is a mixed 
population of wild type and mutant bacteria.  We next isolated single clones of mutant 
235 by limiting dilution in ACCM-2 media.  After expanding these clonal populations and 
screening the cbu0352 locus by PCR as above, we observed that each clonal population 
 
 
 
 
Figure 10. Mutant #235 is deficient in ORP1L recruitment 
Proportion of ORP1L-positive PVs in HeLa cells 72 hpi with wild type 
(WT) or mutant C. burnetii. Cells were transfected with ORP1L-
mCherry, infected, stained by immunofluorescence for C. burnetii and 
CD63, and visually scored for the presence or absence of ORP1L on 
the PV.  Data are represented as the mean from two independent 
experiments with bars representing range.  Each group was compared 
to WT  by repeated measures one-way ANOVA with Greenhouse-
Geisser correction and Dunnett’s multiple comparisons.  * = p < 0.05. 
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Figure 11.  cbu0352 mutant clones are deficient in ORP1L 
recruitment 
(A) Diagram of the cbu0352 genomic locus, showing the Hinmar 
transposon insertion site at nt 457 and the primers used to screen for 
the insertion (SG220 and SG221).  (B) The cbu0352 locus was amplified 
from wild type, Tn235 population, or clonal Tn235 C. burnetii genomic 
DNA and products were separated by electrophoresis on an agarose 
gel.  All clonal population contain only the mutant cbu0352 locus.  (C) 
Proportion of ORP1L-positive PVs in cells infected with wild type (WT), 
Mutant #235, Tn352 clone 1, and Tn352 clone 2 C. burnetii.  Data are 
represented as means from two independent experiments with bars 
representing range.  Each group was compared to Mutant #235 by 
repeated measures one-way ANOVA with Dunnett’s multiple 
comparisons.  * = p < 0.05. 
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only carried mutant cbu0352 loci (Figure 11B).  This result indicates that the mutant 235 
stock was a mixed population.  All subsequent experiments were performed with the 
clonal population. 
 We next interrogated the ORP1L recruitment phenotype of the Tn235 mutant 
clones.  At 3 days post infection, mutant clones have approximately the same 
proportion of ORP1L-positive PVs compared to the mixed population (Figure 11C).  
Together, these data indicate that CBU_0352 is involved in ORP1L recruitment to the C. 
burnetii PV, though this interaction may occur by either a direct or indirect mechanism. 
 
Heterologously expressed CBU_0352 localizes to the host ER 
 CBU_0352 has not been functionally characterized in previous works, but is 
reported to contain an E-block motif, the T4BSS secretion signal, based on 
computational analysis [141], making it a putative effector protein.  CBU_0352 is 
annotated as a cobalt-zinc-cadmium resistance protein, CzcD, having homology to 
transmembrane cation transporters that are present in a broad range of bacterial 
species. 
 In order to determine the possible subcellular localization of this C. burnetii 
protein within the host cell, we ectopically expressed CBU_0352 fused to mCherry in 
HeLa cells.  Because CBU_0352 is involved in recruiting ORP1L to the PV membrane, we 
hypothesized that CBU_0352 would be present on the PV as well.  To test this, we 
infected HeLa cells expressing mCherry-CBU_0352 with wild type NMII C. burnetii.  At 
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four days post infection, we observed no CBU_0352 on the PV membrane (Figure 12).  
We did, however, observe that heterologous CBU_0352 is present throughout the cell 
and exhibits a striated pattern.  ORP1L on the PV co-localizes with the ER, so we tested 
whether CBU_0352 may also co-localize with an ER-localized GFP in these cells.  We 
observed significant co-localization between ER-GFP and mCherry-CBU_0352 (Figure 
13).  This data suggests that, if secreted, CBU_0352 could localize to the host ER, though 
further investigation is needed to determine if bacterially expressed CBU_0352 also 
localizes to the ER.  
 
 
Figure 12. Heterologously expressed CBU_0352 does not localize to 
the C. burnetii PV    
HeLa cells were transfected with mCherry-CBU_0352, infected with 
wild type C. burnetii, fixed, and stained by immunofluorescence for C. 
burnetii, and observed.  CBU_0352 does not localize to the lumen or 
membrane of the PV.  It does, however, appear to localized to a 
network throughout the host cytoplasm.  Arrows indicate PV. 
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Figure 13. Heterologously expressed CBU_0352 localizes to the host 
ER 
Live cell fluorescence microscopy images of C. burnetii-infected HeLa 
cells expressing ER-localized green fluorescent protein and mCherry-
CBU_0352 or mCherry empty vector (EV).  CBU_0352 co-localizes 
with the host ER. Red = mCherry-CBU_0352, Green = ER-GFP.  Boxed 
area magnified in inset. 
Inset
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Inset
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Chapter IV. ORP1L participates in membrane contact sites between the PV and ER and 
modulates PV dynamics during C. burnetii infection 
 
ORP1L exhibits a striated localization pattern on the PV which is abrogated by mutating 
the FFAT motif 
Using confocal microscopy to more precisely define ORP1L localization on the PV 
membrane, a striking ER-like reticulate pattern was observed.  This was seen most 
clearly when looking at the surface of the PV membrane (Figure 14A).  We hypothesized 
that the PV ORP1L reticulate pattern was due to ORP1L interacting with the ER via the 
FFAT motif.  To test this, we mutated the FFAT motif such that it could no longer bind to 
VAP and examined the ORP1L pattern on the C. burnetii PV.  While the ORP1L FFAT 
mutant still localized to the PV, the reticulate pattern was lost (Figure 14B), suggesting  
PV-associated ORP1L also binds to VAP on the ER. 
 
ORP1L localizes to PV-ER membrane contact sites 
To further confirm this observation, we tested for co-localization between PV-
associated ORP1L and the ER marker KDEL-RFP (red fluorescent protein) [see Materials 
and Methods].  We observed significant overlap between PV-associated ORP1L-GFP and 
KDEL-RFP (Figure 15), demonstrating that ORP1L can simultaneously interact with both 
the PV and the ER.  Together with the domain studies, these data suggest that PV-
associated ORP1L binds to a PV membrane protein via the ankyrin repeats, while the 
FFAT motif binds to VAP on the ER cytosolic surface.  The finding that ORP1L 
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simultaneously associates with both the PV and the ER suggests the presence of 
membrane contact sites (MCS) between these two membranes.  MCS are sites where 
membranes closely interact with an intermembrane distance of approximately 10-30 
nm, or the length of a single protein.  Given that this is the first indication of MCS 
 
 
Figure 14. ORP1L exhibits FFAT motif-dependent striated pattern 
on the PV 
Live cell confocal microscopy images of ORP1L-GFP on the C. burnetii 
PV.  HeLa cells were transfected with wild type ORP1L-GFP (A) or 
FFAT mutant, ORP1L (D478A)-GFP (B).  Three days after infection 
with mCherry-expressing C. burnetii, the PVs were identified by 
phase microscopy and fluorescence imaged by live cell spinning disk 
confocal microscopy.  When the surface of the PV is examined, wild 
type ORP1L exhibits a striated pattern.  This pattern is disrupted by 
the FFAT D478A mutation, which prevents binding to the ER protein 
VAP.  Red = C. burnetii, Green = ORP1L-GFP.  Scale bare = 10 µm. 
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between the C. burnetii PV and ER, our lab used transmission electron microscopy (TEM) 
and electron tomography (ET) to more closely define the interactions between these 
two membranes.  By TEM, the ER was found in close apposition to the PV membrane at 
several sites in HeLa cells (Figure 16A).  Close interactions were also observed between 
 
 
 
 
 
Figure 15. ORP1L on the PV co-localizes with the ER 
Live cell fluorescence microscopy images of C. burnetii-infected HeLa cells 
expressing ER-localized red fluorescent protein (KDEL-RFP) and ORP1L-
GFP.  The maximum Z projection shows the flattened confocal stack 
through the entire cell, while the PV surface is a confocal slice of the top 
surface of the PV (arrows indicate PV membrane).  Magnification of the 
boxed PV (Inset) shows that ORP1L-GFP on the PV co-localizes with the 
host ER.  Red = ER, Green = ORP1L-GFP.  Scale bars = 10 µm. 
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the PV and ER in Vero epithelial cells and THP-1 human macrophage-like cells (Figure 16 
B, C), indicating this interaction is not cell type specific.  Using ET to generate a higher 
resolution 3-D structure, the laboratory identified numerous PV-ER MCS with less than 
20nm distance between the two membranes as well as sites where the PV and ER 
appear to be in direct contact [122].  These data demonstrate the presence of novel 
membrane contact sites, on the scale of a protein complex, between the C. burnetii PV 
and the host endoplasmic reticulum.   
 
Disruption of ORP1L -containing protein complexes results in larger PVs 
 As ORP1L is specifically recruited by C. burnetii to PV, we next explored the 
function of ORP1L on the vacuole.  Our results suggest that ORP1L binds to both an 
unknown PV-localized protein (via N-terminal ankyrin repeats) and the ER protein VAP 
(through the FFAT domain), forming a multi-protein complex bridging the PV and ER 
membranes.  We next asked if disrupting the ORP1L protein complex affects PV 
formation.   
To disrupt PV-ER MCS we first employed a dominant negative approach.  HeLa 
cells expressing ORP1L-GFP, the FFAT mutant ORP1L (D478A)-GFP, ΔAnk-GFP, or GFP 
alone were infected with C. burnetii and PVs measured at 48 hours post infection (Figure 
17).  Compared to cells expressing cytoplasmic GFP, ORP1L-GFP overexpression did not 
result in statistically significant changes in PV size.  The D478A mutation disrupts the 
FFAT motif in ORP1L.  This mutant localizes to the C. burnetii PV, but cannot bind to VAP 
on the ER.  The ΔAnk mutant is not prevented from interacting with ER, but does not 
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localize to the PV (Figure 17A).  Ectopic expression of either D478A or ΔAnk ORP1L- GFP 
results in larger PVs than expressing wild type ORP1L-GFP or GFP alone Figure 17B).  This 
suggests disrupting PV-ER MCS has a positive effect on PV size. 
 Our next approach to disrupt the ORP1L-containing MCS was to reduce 
expression of the ER-localized ORP1L binding partner, VAP, using a pool of four siRNAs.  
At day 4 post infection, the PVs in VAP depleted cells were significantly larger than PVs 
in control cells throughout infection (Figure 18).  This indicates that disrupting PV-ER 
membrane contact sites allows the PV to expand more quickly early during infection 
while PV expansion is somewhat delayed in control cells.  Together with previous data, 
this indicates that disrupting the PV-ER membrane contact sites results in increased PV 
size, indicating that contact with the ER may contribute to limiting PV expansion.   
 
Reduced ORP1L expression results in reduced PV size but no change in bacterial growth 
 To further understand the role of ORP1L during C. burnetii colonization of host 
cells, we used an ON-TARGETplus siRNA pool to deplete ORP1L.  ORP1L protein levels 
Figure 16. Electron microscopy reveals membrane contact sites 
between the PV and ER 
Transmission electron micrographs of HeLa (A), Vero (B), and THP-1 
(C) cells infected with C. burnetii for 1 day (THP-1) or 2 days (HeLa, 
Vero). (A) The boxed areas are further magnified, showing areas 
where the PV membrane (outlined in blue) and ER membrane (red) 
are in close proximity.  (B, C) Magnified areas are boxed and arrows 
show PV-ER MCS.  Cb = C. burnetii; PV = parasitophorous vacuole.  
Scale bars = 200 nm. 
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Figure 17. Over-expression of mutant ORP1L results in larger PVs  
PV measurements in cells overexpressing ORP1L mutants that disrupt 
the ORP1L multiprotein complex at PV-ER membrane contact sites.  
HeLa cells were transfected with GFP or GFP fusions of wild type 
ORP1L, mutated FFAT ORP1L, or ΔAnk ORP1L, and infected 24 hours 
later with C. burnetii (A).  At 48 hours post infection, the cells were 
fixed with paraformaldehyde and PV membrane stained with anti-
CD63.  The PV size was determined using ImageJ and analyze by one-
way ANOVA (B).  Shown are individual PV measurements from four 
separate experiments, with at least 20 PVs per experiment.  Error bars 
indicate standard deviation from the mean.  * = p < 0.5; ** = p < 0.05; 
*** = p < 0.005; **** =p < 0.0005. 
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were decreased by 90% at the time of infection, with levels remaining less than 30% of 
non-targeting control siRNA for the duration of a 6 day infection time course (Figure 
19A).  At two and three days post infection, the PV size in ORP1L-depleted cells was 
similar to control cells (Figure 19B).  However, while control PVs continued to expand 
approximately four-fold between days three and six, PVs in ORP1L-depleted cells had 
 
 
Figure 18. Depletion of VapB results in larger PVs. 
HeLa cells were treated with siRNA and then infected 2 days later (0 
hpi).  Infected cells were re-transfected with siRNA at 0 hpi and 
samples.  PV measurements in cells treated with non-targeting (NT; 
solid line) or VapB-targeted siRNA (siVapB; dashed line).  At 48, 72 or 
96 hpi coverslips were fixed with paraformaldehyde and processed 
for immunofluorescence with anti-CD63 and anti-C. burnetii.  PV area 
was determined using ImageJ and means compared by ordinary one-
way ANOVA with Sidak’s multiple comparisons test.  Data are 
represented as means from three independent experiments with at 
least 30 PVs per condition in each experiment.  * = p < 0.0001.  Error 
bars represent standard deviation. 
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Figure 18. Depletion of ORP1L results in smaller PVs.
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significantly less expansion, and were half the size of non-targeting PVs at day 6.  
Similarly sized PVs were observed at day 6 post infection in cells treated with a single 
siRNA duplex (Figure 20).  Interestingly, nearly the same number of viable bacteria were 
recovered from both control and ORP1L-depleted cells (Figure 19C).  Rab7 and RILP, 
however, both localized to the PVs of control and ORP1L-depleted cells, indicating the 
smaller PVs in ORP1L-depleted cells are not due to the absence of Rab7 or RILP from the 
PV and confirming that Rab7 and RILP are not sufficient to recruit ORP1L to the PV 
Figure 19. Depletion of ORP1L results in smaller PVs. 
HeLa cells were treated with siRNA and then infected 2 days later 
(day 0 post infection (p.i.)).  Infected cells were re-transfected with 
siRNA at 0 days p.i., and samples processed for immunoblotting, 
immunofluorescence, or growth assays.  (A) ORP1L protein expression 
in cells treated with either non-targeting (N) or ORP1L siRNA (O) over 
a six day C. burnetii infection.  Cell lysates were immunoblotted and 
ORP1L protein levels quantitated by normalizing to the loading 
control GAPDH.  ORP1L protein levels remained less than 30% of the 
non-targeting control for the duration of the experiment.  Shown is a 
representative blot from 6 experiments.  (B)  PV measurements in 
cells with either wild type or depleted ORP1L.  At various times post 
infection, coverslips were fixed with paraformaldehyde and the PV 
membrane stained with anti-CD63 and anti-C. burnetii.  The PV size 
was determined using ImageJ and standard error of the mean 
determined by ordinary one-way ANOVA with Sidak’s multiple 
comparisons test.  The scatter plot shows individual PV 
measurements from three independent experiments, with at least 30 
PVs per condition in each experiment.  Bars indicate average ± SEM.  
**** = p<0.0001.  (C)  C. burnetii growth in ORP1L-depleted cells is 
similar to control cells.  The number of viable bacteria was 
determined by fluorescent foci unit (FFU) assay at the days indicated, 
and normalized to day 0 to determine fold change in bacterial growth.  
The results are expressed as the mean of three experiments done in 
duplicate.  Error bars represent SEM.  
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(Figure 21).  These data suggest ORP1L plays a role in PV expansion.  Further, a large, 
spacious PV is not required for robust bacterial growth. 
 The smaller PVs that are observed upon ORP1L-depletion appear to contradict 
the observations of larger PVs upon disruption of the ORP1L-containing PV-ER 
membrane contact site complexes.  This apparent inconsistency may be explained by 
ORP1L having multiple functions: it can participate in MCS as well as regulating 
trafficking and fusion of LEL vesicles.  While depleting VAP or overexpressing ORP1L 
 
 
Figure 20. Depletion of ORP1L with single siRNA duplex results in 
smaller PVs. 
HeLa cells were treated with a single siRNA duplex at 50nM.  At 6 days 
post infection, coverslips were fixed with paraformaldehyde and the 
PV membrane stained with anti-CD63 and anti-C. burnetii.  The PV size 
was determined using ImageJ and means compared by unpaired 
Welch’s t-test.  The scatter plot shows individual PV measurements 
from two experiments, with at least 40 PVs per condition in each 
experiment.  Bars indicate average ± SEM.  **** = p < .0001 
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Figure 21.  Depletion of ORP1L does not alter Rab7 or RILP PV-
localization. 
HeLa cells were treated with siRNA, transfected with plasmid DNA the 
next day, and then infected 1 day later.  At 2 days post infection, cells 
were fixed and stained for CD63 and Coxiella.  Both Rab7-GFP (A) and 
RILP-GFP (B) localize to the Coxiella PV in cells treated with siRNA 
targeting ORP1L or non-targeting (NT) negative control. Scale bar = 10 
µm.gure 20.  Depletion of ORP1L does not alter Rab7 or RILP PV-
localization. 
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mutants, wild type ORP1L retained its LEL trafficking regulation function.  By depleting 
wild type ORP1L, we observe the effect of losing both functions of ORP1L.  
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Chapter V. Discussion 
 
ORP1L PV localization 
 We have defined the temporal dynamics of ORP1L localization to the PV and 
identified several factors involved in recruitment of this endo-lysosomal protein during 
C. burnetii infection.  Our data show that ORP1L localization to the C. burnetii PV 
requires both the N-terminal ankyrin repeats and a functional C. burnetii Type 4B 
secretion system (T4BSS).  The requirement for the ankyrin repeats indicates that 
protein-protein interactions are primarily responsible for ORP1L association with the PV. 
In uninfected cells, ORP1L ankyrin repeats are known to physically interact with the 
GTPase Rab7, where ORP1L binds and modulates the function of Rab7 on LELs [100].  
ORP1L preferentially interacts with the GTP-bound active form of Rab7.  Fluorescence 
recovery after photobleaching (FRAP) experiments showed that ORP1L overexpression 
results in prolonged residence of eGFP-Rab7 on LEL membranes and slowing the rate of 
replacement of bleached eGFP-Rab7 with unbleached protein [100].  This result 
suggests that ORP1L stabilizes GTP-bound Rab7.  Despite both Rab7 and ORP1L 
localizing to the C. burnetii PV, our data indicates that Rab7 is not sufficient for ORP1L 
localization to the PV (Figure 9).  The ankyrin repeats are also required for ORP1L 
localization during adenovirus infection, where the adenovirus protein RIDα binds to the 
ORP1L sterol-binding domain in the formation of endosome-ER MCS in order to 
modulate the immune response to infection [108, 142].  Several C. burnetii T4BSS 
effector proteins localize to the PV membrane [137], and are potential binding partners 
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for ORP1L.  In an analogous system, the Chlamydia trachomatis protein IncD recruits the 
ceramide-transfer protein CERT to the bacterial inclusion, which in turn binds VAP on 
the ER to form inclusion-ER MCS [143, 144].  Thus, intracellular pathogens may have a 
common strategy to recruit host cell proteins in the formation of MCS with the ER. 
 Besides directly binding a T4BSS effector, a T4BSS effector protein might 
modulate the small GTPase Rab7, the ORP1L binding partner on late endosomes and 
lysosomes in uninfected cells [133].  Rab7 cycles between an active, GTP-bound form 
and an inactive, GDP-bound form.  ORP1L can bind both forms and stabilizes GTP-bound 
Rab7, although it is not known if the Rab7 activation state affects ORP1L function [100].  
A constitutively active mutant of Rab7 is found on the PV, and Rab7 is required for PV 
maturation and expansion through an unknown mechanism[56].  It is possible that a 
T4BSS effector protein regulates Rab7 activation, leading to the recruitment of ORP1L.  
We also cannot rule out the possibility that the lack of ORP1L on IcmD mutant PVs is 
indirectly due to a lack of PV maturation.  However, because IcmD mutant bacteria 
remain viable for several days within the host cell and PVs harboring the IcmD mutant 
do support limited bacterial replication [73], maturation to an acidic phagolysosome is 
most likely not the sole requirement for PV ORP1L localization.  This is further supported 
by ORP1L localization to the majority of wild type C. burnetii PVs at 12 hours post 
infection, shortly after T4BSS secretion is believed to begin at approximately 8 hours 
post infection.  Further studies are needed to identify ORP1L PV binding partner(s) and 
understand how ORP1L is recruited to the PV membrane.   
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 In this work, we screened 18 C. burnetii transposon mutants for deficiency in 
ORP1L localization to the PV.  A mutation in the C. burnetii gene cbu0352 leads to a 
reduced number of ORP1L-positive PVs, indicating that this protein is involved in ORP1L 
recruitment.  The cbu0352 mutant was included in the screen for ORP1L-interacting 
genes because it contains a computationally predicted E-block secretion signal sequence 
[141], making it a putative T4BSS effector protein.  CBU_0352 is annotated as CzcD.1 
and is homologous with transmembrane cadmium-zinc-cobalt (Czc) transporters in 
other bacteria.  These homologs have been shown to function as heavy metal ion 
transporters in a variety of species as well as playing a role in the transcriptional 
response to metal ion exposure.  There are several potential mechanisms by which 
CBU_0352 could affect ORP1L localization (Figure 22): A) CBU_0352 may be secreted 
and directly interact with ORP1L, B) CBU_0352 may be secreted and indirectly affect 
ORP1L localization, C) CBU_0352 may not be secreted, and affect ORP1L localization by 
regulating the T4BSS, D) CBU_0352 supports the general health of the bacteria, 
nonspecifically allowing for manipulation of ORP1L localization. 
 If CBU_0352 is, in fact, a secreted T4BSS protein, it could traffic to the PV or ER 
membranes, recruiting ORP1L and/or participating in PV-ER membrane contact sites 
(Figure 22A).  We have shown that heterologously expressed CBU_0352 localizes the ER, 
suggesting that it could interact with ORP1L at the PV-ER membrane we have observed.  
C. burnetii has previously been shown express ER-localized T4BSS effector proteins.  
Specifically, ER-localizing protein A (ElpA), targets to the ER during infection and disrupts 
the ER structure and secretory pathway function when heterologously expressed in 
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Figure 22. Possible mechanisms of CBU_0352 function in ORP1L 
recruitment 
A) CBU_0352 may be secreted into the host cell, localize to the ER or 
PV membranes, and directly interact with ORP1L.  B) CBU_0352 may 
be secreted into the host cell and indirectly affect ORP1L recruitment 
or localization.  C) CBU_0352 may be necessary for proper T4BSS 
function, indirectly influencing ORP1L recruitment by another T4BSS 
effector.  D) CBU_0352 may be needed for optimum C. burnetii 
health, indirectly influencing ORP1L recruitment. 
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eukaryotic cells [145].  CBU_0352 or additional effector proteins may manipulate ER 
functions to support C. burnetii.  It is possible, however, that because CBU_0352 is a 
transmembrane protein that this localization is due to CBU_0352 lacking a eukaryotic ER 
export signal sequence, resulting in the protein getting “stuck” in the host ER and 
making this result uninformative.  If CBU_0352 does not directly interact with ORP1L, it 
may do so indirectly, perhaps by directing fusion of vesicles containing ORP1L with the  
PV (Figure 22B). 
 Based on the function of homologous proteins, it is possible that CBU_0352 is 
not secreted by C. burnetii.  In Pseudomonas sp., czcD and other transporters are 
transcriptionally controlled by the two-component signal transduction system, czcRS. 
czcD activity also feeds back into this transcriptional system, down regulating its activity 
[146].  In Ralstonia sp., czcD functions as a regulator of the Czc system and deletion of 
the gene results in constitutive transcription of czc genes in the absence of stimulation 
[147].   There are established examples of two-component signal transduction systems 
both controlling expression of heavy metal resistance genes such as CzcD, as well as 
being regulated themselves by metal ions [148].  The C. burnetii T4BSS is regulated by 
PmrAB two-component system [149], and  is conceivable that CBU_0352 could influence 
the expression of T4BSS components or effector proteins through PmrAB or some other 
regulatory pathway (Figure 22C).  Additionally, CBU_0352 could participate in 
maintaining metal ion homeostasis, so disrupting this gene leads to generally unhealthy 
bacteria that cannot drive ORP1L recruitment to the PV (Figure 22D).  Much more work 
67 
is needed to determine the function of CBU_0352 and its role during C. burnetii 
infection. 
 
ORP1L effect on PV dynamics 
 ORP1L depletion led to smaller PVs, yet did not have an effect on bacterial 
growth, suggesting that a large, spacious PV is not strictly required for C. burnetii 
growth.  The experiments reported here were conducted in a permissive cell type in  
A similar observation was made recently in Lamp1/Lamp2 double knockout fibroblasts 
[150].  Further, a mutant in the C. burnetii T4BSS effector protein CvpB forms multiple 
PVs per cell, but does not have a growth defect in vitro [151, 152]. Collectively, C. 
burnetii appears to modulate a complex interplay of different, and possibly redundant, 
pathways to build the optimal vacuole to support bacterial replication.  This is supported 
by the finding that a CvpB mutant has an attenuated virulence phenotype in the in vivo 
insect model Galleria mellonella [152].  The reason behind smaller PVs in the absence of 
ORP1L is not clear.  Interactions between host vesicular trafficking and the PV 
membrane are not well understood, but it has been assumed that a significant portion 
of the PV membrane comes from fusion with host vesicles.  It is possible that the ER 
might serve to stabilize the PV membrane in order to allow for expansion or that ER 
contact may prevent maximum expansion of the PV, with the absence or decrease in 
PV-ER MCS leading to altered PV membrane dynamics by altering fusion with host 
trafficking pathways.   
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 The function of ORP1L and PV-ER MCS is not yet clear, and further investigation 
of the molecular machinery involved in endosome-PV fusion is needed.  ORP1L belongs 
to a family of sterol-transfer proteins and binds phosphatidylinositol phosphates, 
oxysterols, and cholesterol.  ORP1L may transfer cholesterol or other sterols between 
two membranes, similar to the proposed function of CERT at the C. trachomatis 
inclusion [143, 144]. ORP1L is hypothesized to transfer cholesterol from lysosomes to 
the ER independent of the lysosomal cholesterol transporter NPC1, during adenovirus 
infection, with the cholesterol then esterified and incorporated into lipid droplets [90, 
153].  The cholesterol transfer function of ORP1L is further supported by a recent report 
that knocking out ORP1L results in changes in cholesterol homeostasis.  These include a 
reduction in the relative proportion of cellular cholesterol that is esterified compared to 
wild type cells as well as the visualization of cholesterol accumulating within endosomal 
vesicles [111].  PV-ER MCS may also participate in the exchange of calcium or other 
small molecules, or be a mechanism to manipulate ER stress and apoptosis.   
 Disruption of these PV-ER MCS, either by mutant ORP1L overexpression or VAP 
depletion, results in larger PVs while ORP1L depletion results in smaller PVs, indicating 
ORP1L may play more than one role in PV membrane dynamics.  In addition to 
participating in PV-ER MCS, ORP1L may play a direct role in fusion between the PV and 
host cell endosomes.  It follows that smaller PVs resulting from ORP1L depletion may be 
the result of decreased fusion.  In uninfected cells, ORP1L regulates tethering and 
subsequent fusion of endosomes with one another by mediating interactions between 
RILP and the HOPS complex [90].  Both Rab7 and RILP localize to the C. burnetii PV in the 
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absence of ORP1L, suggesting these proteins are not directly responsible for the size 
defect. 
 ORP1L depletion or PV-ER MCS disruption may have differential effects on 
subsets of endocytic host vesicles.  For example, two subpopulations of late endosomes 
(LE) have been described in human cells defined by the localization of different 
cholesterol-binding and transporter proteins.  These two populations represent 
sequential stages of cargo transport: StARD3 and ABCA3 define an “early” LE that 
recycles back to the plasma membrane, while ORP1L and NPC1 define a “late” LE that 
traffics to the ER [154].  We do not know whether StARD3/ABCA3-positive LEs interact 
or fuse with the PV, but these two transport systems could play somewhat redundant 
roles in supporting C. burnetii growth.  Alternately, these two endosomal populations 
could interact with the PV by disparate mechanisms, leading to differential effects 
following disruption of PV-ER MCS.  While the possible contributions of each of these 
factors to C. burnetii biology is not fully elucidated, there are several lines of evidence 
that these LE proteins do contribute bacterial survival.  Although no role for StARD3 
during C. burnetii infection has been reported, knockdown of either NPC1 or ABCA3 
significantly restricts C. burnetii growth [115, 139].  Interactions between the PV and 
these two populations of vesicles or other types of vesicles known to interact with the 
PV could contribute to the various effects on PV dynamics that we have observed.  
Given the dual roles of ORP1L in endosomal fusion and endosome-ER membrane 
contact sites, further work is needed to understand the contribution of each role to the 
structure, size, and function of the PV as a replicative niche for C. burnetii. 
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 In summary, this study demonstrates that ORP1L specifically localizes to the PV 
membrane in a bacterially-driven, T4BSS-dependent manner.  The putative C. burnetii 
secreted protein, CBU_0352, influences ORP1L localization via an unknown mechanism.  
Additionally, we have shown that novel membrane contact sites (MCS) are present 
between the PV and host ER membranes.  The sterol-binding protein ORP1L is one 
component of these MCS, and appears to play a role in PV membrane dynamics.  Future 
experiments clarifying the function of CBU_0352, identifying the specific role of ORP1L 
on the PV, and elucidating the function of PV-ER interactions will give new insight into C. 
burnetii pathogenesis and host cell manipulation.   
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Chapter VI. Future Directions 
 
ORP1L-containing PV-ER membrane contact sites 
 The endoplasmic reticulum plays essential roles in mammalian cells, including 
lipid and protein synthesis, calcium storage, and the cellular stress response.  
Membrane contact sites (MCS) between the ER and other cellular organelles serve as a 
location for exchange of small molecules and lipids.  The formation of MCS relies on 
multi-protein complexes that tether the two membranes together within a distance of 
15 nm [155].  Prior studies have implicated ORP1L, a member of the sterol transfer 
protein family, in the formation of LEL-ER MCS [102, 156].  Additionally, ORP1L localizes 
to the PV harboring the intracellular bacterial pathogen Coxiella burnetii. ORP1L can 
simultaneously bind to the C. burnetii PV and the ER, suggesting ORP1L is also a 
component of PV-ER MCS.  This is the first description of MCS between the C. burnetii 
PV and an intracellular organelle [122], and is supported by a recent study showing that 
the ER marker calnexin is closely associated with the PV during C. burnetii infection 
[157].   
 Based on these data, we propose a model where PV-associated ORP1L binds to 
VAP on the ER, forming MCS between the PV and ER (Figure 23).  This model is further 
supported by our observation of PV-ER MCS by electron microscopy.  While our data 
suggest ORP1L and VAP are components of these MCS, other proteins or protein 
complexes may be involved and ORP1L may not be a component of every PV-ER MCS.  
Indeed, many lipid transfer proteins with FFAT motifs have been found at MCS between 
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Figure 23. Model for ORP1L in membrane contact sites between the 
C. burnetii parasitophorous vacuole (PV) and host cell endoplasmic 
reticulum.   
ORP1L is recruited directly or indirectly to the C. burnetii PV by the 
T4BSS, where it participates in membrane contact sites between the 
PV and host ER.  ORP1L appears to interact with ER localized VAP. 
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the ER and the plasma membrane, Golgi, and mitochondria (reviewed in [158]).  The C. 
burnetii genome encodes three proteins with putative FFAT motifs: CBU_0274, which 
encodes Excinuclease ABC subunit A, and two hypothetical proteins of unknown 
function, CBU_0328 and CBU_1370 (Dr. Paul A. Beare, unpublished).  It is unlikely that 
the Excinuclease ABC subunit is secreted by the bacteria, however, the two hypothetical 
proteins could represent a mechanism by which C. burnetii could manipulate membrane 
contact sites between the ER and the PV or other membranes.  
Characterizing CBU_0352 
Is CBU_0352 a secreted protein? 
 In order to understand the role of CBU_0352 in ORP1L recruitment and its larger 
role during C. burnetii infection, it will be imperative to empirically determine if 
CBU_0352 is secreted into the host cell.  By determining whether CBU_0352 is secreted, 
we may find out whether this protein is directly manipulating host cell biology or 
functioning in a bacterial cell-intrinsic manner.  Commonly, affinity or fluorescent tag 
fusion proteins are used to visualize the localization of a protein of interest.  C. burnetii 
effector proteins, however, are often expressed in such low abundance as to be 
undetectable using this method.  I have attempted to visualize 3xFLAG-tagged 
CBU_0352 by IFA in HeLa cells infected with C. burnetii expressing this protein, but this 
method was not successful (did not result in signal above background).  Consequently, 
the product of enzymatic reactions, such as for the β-lactamase fusion proteins 
described in Chapter I, are used as indirect indicators of translocation into the host cell.  
I plan to use the B. pertussis adenylate cyclase toxin, CyaA, as a qualitative reporter of 
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translocation [159], which is the standard in the C. burnetii field.  When CyaA is present 
in the host cytoplasm, it is activated by calmodulin and converts adenosine triphosphate 
(ATP) into cyclic adenosine monophosphate (cAMP).  cAMP levels can be measured 
colorimetrically as a surrogate for translocation of the fusion protein. 
 In order to determine if CBU_0352 is a translocated protein, I propose to use 
plasmids expressing CyaA alone, CBU_0352 fused to CyaA, and a known effector 
protein, CvpD, fused to CyaA [160].  Each plasmid will be expressed in wild type or DotA 
mutant NMII C. burnetii.  The DotA mutant, which cannot translocate T4BSS effector 
proteins, and wild type bacteria expressing CyaA alone, which will not be translocated, 
will be used as negative controls.  CyaA-CvpD expressed in wild type bacteria will serve 
as a positive control for translocation.  If a significant increase in cAMP levels is 
observed in wild type C. burnetii expressing CyaA-CBU_0352 compared to mutant C. 
burnetii expressing the same fusion protein, this will indicate that CBU_0352 is indeed 
secreted during infection.   
Does the CBU_0352 mutation broadly affect T4BSS function? 
 If we determine that CBU_0352 is not a secreted protein, one possible 
explanation of how a mutation in this gene could influence T4BSS-dependent ORP1L 
recruitment to the C. burnetii PV is that CBU_0352 plays a broader role in regulating or 
influencing T4BSS function.  To test this, I propose to examine the function of the T4BSS 
in a CBU_0352 mutant background.  The same CyaA-containing constructs described 
above will be expressed in the CBU_0352 transposon mutant background (Tn235 clone) 
and translocation will be assessed as described.  If CBU_0352 mutant bacteria is unable 
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to translocate known effector fusion proteins (such as CyaA-CvpD), this will 
demonstrate that the T4BSS system is inhibited.  This result would suggest that one or 
more of the effector proteins whose translocation is CBU_0352-dependent may be 
influencing ORP1L PV recruitment. 
What is the effect of cbu0352 deletion? 
 In order to explore the function of CBU_0352, I propose to delete the cbu0352 
locus from wild type NMII C. burnetii using the “loop-in, loop-out” method developed by 
Beare et al. [161].  A clean cbu0352 deletion will be a useful tool to parse functions of 
CBU_0352.  The mutant currently being used contains a transposon insertion at nt 457 
and this placement leaves the possibility open that the N-terminal portion of the 
CBU_0352 protein is expressed.  Expression of this truncated protein could result in a 
confounding phenotype resulting from a dominant negative interaction, a gain of 
function interaction, or a partial null phenotype.  For example, we see a 50% decrease in 
the number of ORP1L-positive PVs in cells infected with CBU_0352 mutant C. burnetii 
compared to wild type, and it is possible that a ‘clean’ CBU_0352 knockout would not 
recruit ORP1L to the PV at all.  By deleting the entire cbu0352 locus, the resulting 
phenotype will be more easily interpreted. 
Can cbu0352 mutant phenotypes be complemented? 
 In order to confirm that the reduction in ORP1L-positive PVs is due to the 
mutation in cbu0352 as well as the replication deficit reported by Martinez et al. [140], I 
propose to complement the transposon mutant (and the cbu0352 knockout when it is 
generated) using FLAG-tagged CBU_0352.  While allelic replacement has not yet been 
76 
achieved in C. burnetii, we can introduce a wild type copy of cbu0352 that will be 
inserted into the genome in a random location [161].  If complementation rescues these 
phenotypes, we will be able to fulfill molecular Koch’s postulates and confidently ascribe 
the growth and ORP1L recruitment phenotypes to the mutation in cbu0352. 
 
Identifying ORP1L-interacting proteins 
 I have shown that CBU_0352 interacts genetically with ORP1L, however, physical 
interactions with additional bacterial or host proteins may influence ORP1L function or 
recruitment to the C. burnetii PV.  To identify ORP1L-interactors, I propose an affinity 
purification technique to isolate ORP1L-containing protein complexes.  Constructs 
expressing ORP1L fused to a BioEase protein tag could be used for this purpose.  The 
BioEase tag is a 72 amino acid sequence comprising the biotin-targeting domain from 
Klebsiella pneumoniae oxaloacetate decarboxylase (KPBT) and is efficiently biotinylated 
by eukaryotic cells in vivo [162] when the growth media is supplemented with biotin.  
Biotinylated proteins can be pulled down using a streptavidin conjugated substrate.  
 Because the ORP1L ankyrin repeats are responsible for PV localization, I could 
use wild type, Ank, and ΔAnk ORP1L to identify proteins involved in this process.  There 
are several potential results that would indicate a particular protein could play a role in 
ORP1L recruitment.  PV-localized ORP1L-interacting proteins would most likely be 
revealed as binding to both wild type and Ank ORP1L while not interacting with ΔAnk 
ORP1L.  Proteins that interact with ORP1L, but are not on the PV membrane or interact 
with ORP1L in an ankyrin-independent manner, would bind to wild type and ΔAnk 
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ORP1L, but not Ank ORP1L.  Such proteins could participate in the PV-ER MCS or in other 
ORP1L-containing protein complexes.  Regardless of the domains involved, any bacterial 
protein that specifically binds ORP1L would be of interest, as these may be secreted 
effectors and represent a mechanism for direct bacterial manipulation of ORP1L. In 
addition to bacterial ORP1L-interacting proteins, we may also identify host proteins that 
interact with ORP1L only during infection by comparing results from infected and 
uninfected host cells.  These infection-specific host protein interactions could be either 
bacteria-driven in support of replication or may be host-driven as part of an anti-
bacterial response.  Regardless of the specific outcome, this line of experimentation has 
the broad potential to reveal information about the function of ORP1L by elucidating its 
infection-specific protein-protein interaction network. 
 
Investigating ORP1L function 
What is the conformation of ORP1L on the PV? 
 We have gained some insight into the role ORP1L may be playing in C. burnetii 
PV dynamics, but additional questions remain.  The opposing effects of disrupting PV-ER 
MCS and ORP1L knockdown on PV size indicate that ORP1L is playing two possibly 
opposing roles.  Previous reports have shown that ORP1L exists in two conformations, 
corresponding to its roles in MCS and LEL trafficking [90].  In order to determine which 
function of ORP1L is most relevant during C. burnetii infection, determining the 
conformation of ORP1L on the PV could be informative.  I propose to use a FRET-based 
approach based on that used by Rocha et al. to determine the conformation of ORP1L 
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[112].  Towards this end, I have made two intramolecular FRET constructs using the 
optimized FRET donor-acceptor pair, mTurquoise and mVenus, with wild type and ΔORD 
ORP1L.  ΔORD ORP1L is lacking the sterol-binding domain and cannot take on the 
condensed conformation, so it will serve as a negative control for FRET signal.   
 These FRET sensors could be used to determine the conformation of ORP1L on 
the PV throughout the course of C. burnetii infection.  We know that ORP1L participates 
in MCS late during infection when the PV is already very large, but we do not know if 
this is the case during earlier stages of infection.  I propose to observe the conformation 
of ORP1L over a time course of at least 6 days. 
What is the effect of ORP1L depletion in macrophages? 
 The inhalation of contaminated aerosols is the most common route of C. burnetii 
human infection.  Paired with phagocytosis as the primary cell entry route, this causes 
alveolar macrophages to be enriched among the first cells infected [120].  As such, the 
mouse alveolar macrophage cell line, MH-S, is a good model of C. burnetii interactions 
with host cells.  This cell line may also be particularly relevant to this project, as ORP1L is 
highly expressed in monocytes and macrophages [99].   
 In order to deplete macrophages of ORP1L, I propose to use lentiviral shRNA 
targeting ORP1L.  To this end, I have optimized transient knockdown in these cells 
compared to cells treated with a non-targeting “scrambled” (SCR) shRNA and achieved 
60-80% knockdown (Figure 24).  In subsequent experiments I would use shORP1L 1 and 
5, that both exhibited significant knockdown.  To explore the effect of ORP1L depletion 
in MH-S cells, I propose initial characterization of C. burnetii growth by FFU assay and PV 
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size by IFA.  
What is the effect of ORP1L deletion? 
 A recent publication reported the CRISPR/Cas9-mediated knockout of ORP1L in 
epithelial cells (HeLa and 293T) and the subsequent alterations to cholesterol trafficking 
[111].  These cell lines may be used to determine if complete knockout, as opposed to 
the partial knockdown achieved by siRNA in this work, has a greater effect on PV 
 
 
Figure 24.  ORP1L knockdown in MH-S cells by lentiviral shRNA 
Reduced ORP1L expression is observed in shRNA-treated murine alveolar 
macrophage cells compared to untreated cells.  We observed little 
difference between untreated cells and cells treated with a non-
targeting scrambled shRNA.  Mean ORP1L protein expression level 
observed in two experiments are displayed.  Expression levels in each 
condition were compared to untreated cells (MH-S) by repeated 
measures one-way ANOVA with Dunnett’s multiple comparison.  Error 
bars represent range.  * = p < 0.05.  SCR = scrambled, non-targeting 
shRNA. 
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dynamics or C. burnetii growth in epithelial cells.  Further insights could be gained by 
using CRISPR/Cas9 to knockout ORP1L in the alveolar macrophage cell line, MH-S.  I have 
designed and made several constructs expressing Cas9 and a single ORP1L-targeting 
sgRNA from a single plasmid (see Materials and Methods) which could be used to create 
an ORP1L knockout cell line.  I propose to test the effect of ORP1L deletion on PV 
formation and C. burnetii growth in macrophages by microscopy and FFU assays. 
 
A tool for unbiased investigation of C. burnetii secreted proteins 
 C. burnetii relies upon its T4BSS as well as other secretion systems to manipulate 
the host cell and support its own survival and replication.  Identifying the secreted 
protein effectors and understanding their function is paramount to understanding the 
intricate interactions between this bacterial pathogen and its host.  In recent years, non-
canonical amino acids have been used as a tool to selectively label and identify microbial 
proteins.  Mahdavi et al. identified several proteins secreted by the human pathogen, 
Yersinia enterocolitica, by specifically labeling the proteins of bacteria expressing a 
mutant form of the methionyl-tRNA synthetase (MetRS), MetRSNLL, which activates the 
methionine surrogate, Anl [128] for incorporation into nacently translated proteins.  
ANL-containing proteins can be labeled with affinity tags for purification or fluorescent 
tags for visualization using copper-catalyzed “click chemistry” in either fixed cells or in 
cell lysate samples.  This method has also been used for pulse-chase labeling of 
Toxoplasma gondii proteins during growth in vitro.  In this system, T. gondii N-terminally 
processed proteins, including secreted proteins, were not labeled because the bacterial 
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MetRSNLL could only charge initiator Met tRNAs with ANL, but could not charge 
eukaryotic elongator Met tRNAs [163], resulting in ANL incorporation only at the N-
terminus of nascent polypeptides.  While this should not be a problem within a 
prokaryotic system, we will need to be wary of such incompatibilities as we attempt to 
use this system in C. burnetii.  
 In order to implement this protein labeling system in C. burnetii, we first needed 
to express MetRSNLL in the bacteria.  I created a plasmid encoding HA-tagged MetRSNLL, 
with expression controlled by the constitutively active C. burnetii promoter, p1169.  I 
have transformed this plasmid into wild type bacteria and confirmed expression by 
Western blot, probing with anti-HA antibody.  Next, we will need to verify that C. 
burnetii expressing MetRSNLL will indeed incorporate ANL into proteins when ANL is 
present in axenic culture and/or during host cell infection.  Once this protein labeling 
system is optimized and verified to be functioning, there are several studies for which it 
can be used to interrogate ORP1L function as well as general C. burnetii biology and 
pathogenesis. 
What bacterial proteins bind ORP1L during C. burnetii infection? 
 First, this system could be used to identify C. burnetii proteins which physically 
interact with ORP1L in infected cells.  I propose pulldown experiments to identify 
bacterial binding partners of ORP1L.  To do this, the BioEASE-ORP1L approach described 
above could be adapted to investigate whether ANL-labeled bacterial proteins are 
pulled down with biotinylated ORP1L.   
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Which C. burnetii proteins are secreted and when? 
 Labeling bacterial proteins in a non-biased manner allows for the opportunity to 
isolate and identify secreted proteins.  By lysing infected cells with trichloroacetic acid 
(TCA), one may retain the intact bacteria in the insoluble fraction along with host 
cellular debris, and identify bacterial proteins in the soluble fraction (which includes 
secreted proteins) by SDS-PAGE and Western blot, probing for the affinity tag added to 
ANL labeled proteins by click chemistry.  A similar approach was successfully employed 
to identify FLAG-tagged C. burnetii proteins that are translocated into axenic media by 
Sec-mediated secretion [164].  Affinity tag labeled bacterial proteins could be isolated 
by immunoprecipitation and identified by mass spectrometry analysis.   
 Pulse-chase labeling of proteins followed by isolation and identification as 
described above could begin to clarify the temporal dynamics of protein secretion 
during host cell infection.  For example, such experiments may reveal whether proteins 
are secreted in sequential cohorts or if all secreted proteins are translocated 
constitutively throughout infection.  
 Finally, this system could be used to identify secreted proteins that localize to 
specific host cellular fractions.  For example, bacterial proteins could be isolated from 
the host nuclear fraction, allowing for identification of effectors that localize to the 
nucleus, perhaps modulating host gene expression.  Two nuclear-localizing C. burnetii 
effector proteins have been previously identified: CBU_1314 associates with host 
chromatin and regulates the expression levels of at least 16 host genes [78], and AnkG 
traffics to the host nucleus where it inhibits pathogen-induced apoptosis of the host cell 
83 
[165, 166].  Unbiased labeling of bacterial proteins would allow for the relatively rapid 
identification of additional host-modulating effectors.  Recent methods have been 
published which allow for the isolation of ER membranes, independent of other 
membrane organelles [167, 168], which was not previously possible with density 
gradient separation [169].  Identification of ER-localized effector proteins would be 
particularly relevant to this work. 
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